

BMJ Open

Statin use associates with a reduced incidence of venous thromboembolism – A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005862
Article Type:	Research
Date Submitted by the Author:	05-Jun-2014
Complete List of Authors:	Lassila, Riitta; Medical Faculty, University of Helsinki Jula, Antti; The National Institute for Health and Welfare, Pitkaniemi, Janne; University of Helsinki, Hjelt Institute, Public Health Haukka, Jari; University of Helsinki, Hjelt Institute, Public Health
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Epidemiology
Keywords:	Thromboembolism < CARDIOLOGY, EPIDEMIOLOGY, Anticoagulation < HAEMATOLOGY

SCHOLARONE™
Manuscripts

Peer review only

Statin use associates with a reduced incidence of venous thromboembolism – A population-based cohort study

¹Riitta LassilaMD, PhD, ²Antti Jula, MD, PhD, ³ JannePitkäniemi, PhD,
and ³Jari Haukka, MD, PhD

¹Coagulation Disorders Unit, Department of Medicine, Division of Hematology and Laboratory Services HUSLAB and Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland

²The National Institute for Health and Welfare (THL), Finland

³Hjelt Institute, University of Helsinki, Finland

Corresponding author:

Jari Haukka
University of Helsinki, Hjelt Institute
PO Box 40, FI-00014 University of Helsinki, Finland
email: jari.haukka@helsinki.fi
tel.: +358 50 4155314
fax.: +358 09 191 27518

Keywords: venous thromboembolism, epidemiology, statins, cohort study

Word count: 2978

Abstract

Objectives: Venous thromboembolism (VTE) continues to be a frequent, medical emergency demanding condition to reach the diagnosis and initiate anticoagulation therapy. The use of statins is reported, in addition to reducing the incidence of arterial thrombosis, also to decrease both the incidence and reoccurrence of VTE. The aim of our study is to explore the association between statin usage and the incidence of new VTE at the population level during a 10-year follow-up.

Design: Population based historic cohort

Setting: The Health 2000 survey was based on a nationally representative sample.

Participants: 8028 individuals aged 30 years or over in Finland.

Primary and secondary outcome measures: The primary end-point event was the first ever hospitalization due to one of the following causes: pulmonary embolism (ICD10 I26), cerebral venous nonpyogenic thrombosis (I63.6), phlebitis and thrombophlebitis of superficial vessels of lower extremities (I80.0-180.9).

Results: The preselected explanatory variables applied to Poisson regression model were statin usage (no/yes) during follow-up (2000-2011) and several baseline data (age, sex ; usage of blood glucose lowering drug, vitamin K antagonists, and anti-platelet agents). We observed 136 VTE events, the incidence of 1.72 (95% CI 1.44-2.04) per 1000 person-years. Current statin usage did not associate with the incidence of VTE according to the univariate model (RR 0.93, 0.56-1.52), but when adjusted with baseline variables (age, sex, medications) the RR declined to 0.60 (0.36-1.00, $p=0.04$).

Conclusions: Statin use offers protection against first ever VTE event and appears as a primary prevention tool in patients without anticoagulation or anti-platelet medication.

Strengths of this study

- population based, no selection bias in start of follow-up
- long and complete follow-up information

Limitations of this study

- limited number of background variables
- the comprehensive use of prescribed drugs in this study, could not be verified with certainty

Introduction

Venous thromboembolism (VTE) continues to be a frequent condition which demands medical emergency attention to reach the diagnosis and initiate anticoagulation therapy. The mortality during a few months after VTE varies between 5-20%, and the patients often have other co-morbidities, such as cardiovascular disease and cancer. The yearly incidence of VTE is 1-2/1000 inhabitants in western societies. Nowadays, the traditional heparin and vitamin K antagonist (VKA) therapy followed with the course of temporal (3-6 months) or permanent VKA can be opted with novel oral anticoagulants[1].

The decision of either continuing the anticoagulation for a few months or permanently depends on the acquired or inherited risk factor profile of the patient. This includes age above 60 years and concomitant illness, including cancer and inflammatory diseases as well as obesity, hormonal remedies and family history or severe thrombophilias (such as homozygosity of factor V Leiden or prothrombin mutation, double defects, antiphospholipid antibody syndrome), subjecting the

1
2
3
4
5
6
7 patient to recurrent VTE. Despite the clinical evaluation the recurrence rate of VTE continues to
8
9 be 15-20% after an idiopathic event and around 5% after a provoked thrombosis[1]. Bleeding
10
11 tendency needs to be regularly weighted also against the risk of thrombosis recurrence, while
12
13 maintaining the anticoagulation.

14
15
16 The use of statins has been reported to reduce the incidence of not only the arterial thrombosis,
17
18 but also interesting data on the decline of both the incidence and reoccurrence of VTE have
19
20 emerged. Retrospective observational and case-control studies as well as experimental evidence
21
22 refer to the possibility that statins exert an antithrombotic effect also in the venous system. A
23
24 recent meta-analysis reported the association of VTE and a 20-36% protection with statin use [2].
25
26 A primary prevention trial of VTE with rosuvastatin in a randomized placebo-controlled design
27
28 showed a 48% reduction in the incidence of VTE[3]. Moreover, statin treatment alleviated the risk
29
30 of recurrent pulmonary embolism by 50% whether the patient used long-term vitamin K
31
32 antagonist treatment or had stopped anticoagulation, as reported by a Dutch population-based
33
34 study with initially hospitalized patients[4]. Finally, statins decrease the occurrence of venous
35
36 thromboembolism even in patients with cancer[5].

37
38
39 Statins reduce the procoagulant activity of platelet membranes and downplay the signaling via LDL
40
41 receptors, which are engaged with the platelet activation[6]. Statins also enhance fibrinolysis by
42
43 reducing the plasminogen activator inhibitor-1 and triglyceride concentration. Also, other
44
45 pleiotropic and anti-inflammatory mechanisms, including dampened tissue factor expression by
46
47 monocytes, have been described which can attenuate the risk of thrombosis.

48
49
50
51 The aim of the study is to explore the association between statin usage and incidence of the first
52
53 ever VTE in Finland. Our study utilizes a nationally representative sample of 8028 persons aged
54
55
56
57
58
59
60

1
2
3
4
5
6
7 >30 years [7] of The Health 2000 Survey and a prospective observational pharmaco-
8
9 epidemiological design.

10 11 12 **Material and methods**

13 14 15 **Study population**

16
17
18 The Health 2000 survey was based on a nationally representative sample of 8028
19
20 individuals aged 30 years or over in Finland. To ensure that sample is representative of the
21
22 Finnish population, a two-stage stratified cluster sampling procedure was used. The baseline
23
24 data collection from study subjects took place between September 2000 and June 2001, and
25
26 consisted of an interview and a comprehensive health examination. Of the study sample 6986
27
28 subjects (87 %) were interviewed at their home or in an institution, 6354 subjects (79 %)
29
30 took part in a comprehensive health examination and 416 subjects (5%) were examined at
31
32 their home. The Health 2000 study was approved by the Ethics Committees of the National
33
34 Public Health Institute (since 2009 the National Institute for Health and Welfare) and the
35
36 Hospital District of Helsinki and Uusimaa, and the participants gave written informed
37
38 consent[7].

39 40 **Follow-up time and end-points**

41
42
43 The primary end-point event of this study was the first hospitalization due one of the
44
45 following causes: pulmonary embolism (ICD10 I26), cerebral infarction due to cerebral
46
47 venous nonpyogenic thrombosis (I63.6), phlebitis and thrombophlebitis of superficial vessels
48
49 of lower extremities (I80.0-180.9). The information about end-points was obtained from
50
51 National Hospital Discharge Register that covers all hospitalizations in Finland starting from
52
53 1969. The 10-year follow-up was started at the beginning of Health 2000 Study and was
54
55
56
57
58
59
60

1
2
3
4
5
6
7 stopped at death, end of year 2011, or end-point, whichever occurred first. The data about
8
9 deaths were obtained from the Statistics Finland. There were 103 individuals with recorder
10
11 primary end-point before the start of follow-up compatible with the general prevalence of the
12
13 disease, and these subjects were excluded from the study population. Thus, the size of study
14
15 population in the start of follow-up was 7925.

16 17 **Laboratory measurements**

18
19 Venous blood samples were drawn from the antecubital vein after a minimum of 4 h fasting.
20
21 HDL cholesterol, total cholesterol, triglyceride and plasma glucose concentrations were
22
23 determined enzymatically (Roche Diagnostics, GmbH, Mannheim, Germany for HDL; Olympus
24
25 System Reagent, Hamburg, Germany for total cholesterol, triglycerides and glucose) with a
26
27 clinical chemistry analyser (Olympus, AU400, Hamburg, Germany)[8]. C-reactive protein
28
29 (CRP) concentrations were determined by a chemiluminescent immunometric assay
30
31 (Immulite, Diagnostic Products, Los Angeles, CA)[8]. LDL cholesterol was calculated with the
32
33 Friedewald formula. Plasma insulin and homocysteine concentrations were determined with
34
35 microparticle enzyme immunoassay (Abbott Laboratories, Dainabot, Tokyo, Japan)[9,10]. S-
36
37 25(OH)D concentrations were measured by radioimmunoassay (Incstar, Stillwater, MN,
38
39 USA)[11].

40 41 42 **Drug information**

43
44 The data about the prescribed and purchased drugs were obtained from registers of the Social
45
46 Insurance Institution. We had records of the following drugs classified by Anatomical
47
48 Therapeutic Chemical (ATC) code[12]: statins (C10AA), blood glucose lowering drugs,
49
50 excluding insulins (A10B), insulin (A10A), VKA (B01AA), and antiplatelet agents, excluding
51
52 heparin (B01AC) and over the counter acetylsalicylic acid. Regarding statins the data included
53
54 all prescribed statins purchased during the follow-up period in 2000 – 2006 and 2008.
55
56
57
58
59
60

1
2
3
4
5
6
7 Because there were no data available regarding the drug amounts purchased for years 2007,
8 and 2009-2011, we calculated the mean amount of purchase based on available years and
9 adapted it for the whole follow-up period. Time dependent variable for the current statin
10 usage was determined for each individual with the prescription data using R language
11 package Epi[13]. The follow-up time of each individual with statin exposure was cut into 6-
12 month periods and the statin usage in each period was determined. For other drugs we had
13 only the number of prescriptions at the baseline year 2000, which was used to construct a
14 dichotomic variable of drug usage at baseline (no/yes).
15
16
17
18
19
20
21
22
23
24
25
26

27 **Statistical modeling**

28
29 We applied the Poisson regression model using end-point event as a dependent variable,
30 length of the follow-up as an offset variable, and statin usage (no/yes) during each time
31 period as time-varying explanatory variable. The following variables were used as time-
32 invariant variables measured at baseline: age (30-40, 40-50, 50-60, 60-70, over 70), sex
33 (male/female), blood glucose lowering drug usage, excluding insulins (no/yes), insulin usage
34 (no/yes), vitamin K antagonists usage (no/yes), antiplatelet agents (no/yes), blood glucose
35 (mmol/L), total cholesterol (mmol/L), HDL cholesterol (mmol/L), LDL cholesterol (mmol/L),
36 triglycerides (mmol/L), CRP (mg/L), vitamin D3 (nmol/L), homocysteine ($\mu\text{mol/L}$), and
37 insulin (mU/L). The values of the laboratory measurements were transformed to categorical
38 variables defined by tertiles. We also estimated the inverse probability weights (IPW) to fit
39 marginal structural models[14]. IPW were estimated using age and sex in the numerator, and
40 age, sex, blood glucose lowering drugs other than insulin usage, VKA usage, and use of
41 antiplatelet agent in the denominator.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

The size of the study population was 7925, including 3589 males and 4336 females (Table 1).

We observed 136 VTE events during the follow-up with the incidence of 1.72 (95% CI 1.44-2.04) per 1000 person-years during the mean follow-up time 10 years (Table 2). There were 64 events with the diagnosis pulmonary embolism (ICD-10 I26), one with sinus thrombosis (I636) and 71 with deep vein thrombosis (I80.0-180.9).

All together there were 67,532 statin prescriptions, and 2083 individuals (26% of population) had at least one prescription. Simvastatin (ATC code C10AA01) with 54% of prescriptions and atorvastatin (C10AA05) with 23% represented the most frequent active lipid-lowering substances. Current statin usage that comprised 14% of all cumulated person-years, did not associate with the incidence of VTE according to the univariate model Rate Ratio (RR) 0.93 (0.56-1.52)(Table 2). The use of oral antidiabetic drugs at the baseline was associated with a three-fold increased incidence (RR 3.32, 1.84-6.00), but insulin usage did not show any association. Using any antithrombotic drugs associated with higher incidence (RR 4.55, 2.70-7.66).

Addition of more explanatory variables in the model substantially altered the association between the statin usage and incidence (Table 3). Adjusting for sex, age, baseline oral antidiabetic, insulin, and use of antithrombotics (Model II) reduced the RR to 0.60 (0.36-1.00). Using IPW for the structural model (Model III) decreased the RR further to 0.58 (0.35-0.96). Adjusting for the baseline laboratory measurements also decreased slightly the estimate for statin effect, e.g. adjusting for CRP gave RR 0.43 (0.23- 0.81). However, because of the missing laboratory measurements we do not report these results in further detail, e.g. for CRP there

1
2
3
4
5
6
7 were several (1694) missing values.(Table 2). Increased levels of LDL associated with an
8
9 increasing incidence of VTE, the same occurred with homocysteine.

10
11
12 In addition, we looked for the possible interactions between statin usage and age, sex, blood
13
14 glucose lowering drugs usage (excluding use of insulin), VKA and platelet aggregation
15
16 inhibitors. Interaction for sex and statin usage was significant ($\chi^2=6.310$, $df=1$, $p=0.012$).
17

18 Interestingly, it turned out that the incidence of VTE among the statin group for males was
19
20 quite low (RR 0.22, 0.06-0.65), but for females such an association was not obvious (RR 0.75,
21
22 0.41-1.38), upon comparing the statin usage without its usage (Table 4.).
23
24

25 26 Discussion

27
28 To our knowledge, this is the first report studying association between statin usage and VTE
29
30 that utilizes a nationally representative population sample. Our results during the 11 years of
31
32 prospective follow-up on the incidence of VTE are in line with the recent meta-analysis[15],
33
34 which showed the risk reduction of 0.89 (0.78-1.01) for VTE among statin users. The
35
36 JUPITER study, the largest meta-analysis of trials, including 465 events, showed 36%
37
38 reduction in VTE (RR 0.64, 0.39-1.06, $p=0.08$)[16]. Our study addressed the new incidence of
39
40 VTE, as the patients who previously had suffered from VTE (136/8028) were excluded from
41
42 study population. The prospective nature and large population-based design of pharmaco-
43
44 epidemiology are the strengths of our study.
45

46
47 In this freely living Finnish population sample we could demonstrate that statin use is
48
49 associated with a reduction of the incidence of VTE, including both deep vein thrombosis of
50
51 the lower extremities, pulmonary embolism and one case of cerebrovascular sinus
52
53 thrombosis. This adds to the confirmation that statins exert anticoagulant activity[2-5].
54
55
56
57
58
59
60

1
2
3
4
5
6
7 Furthermore, it supports the idea that statin therapy could be implemented to the patients
8
9 with the risk of VTE.

10
11
12 We observed that use of oral antidiabetic drugs at the baseline was associated with a three-
13
14 fold increased incidence (RR 3.32, 1.84-6.00), which refers to that insulin-resistant patients
15
16 carry a high risk of VTE, and the oral antidiabetic drugs do not seem to alleviate this risk,
17
18 while insulin may do so[17]. The positive association between antithrombotic drugs and VTE
19
20 is quite probably due to confounding by indication[18], and also the co-occurrence of
21
22 cardiovascular disease and VTE has been noted in several studies[19]. The limitation of our
23
24 study relies on the fact that over-the counter aspirin use is not controlled. This is significant,
25
26 as aspirin has been recently shown to inhibit the reoccurrence of idiopathic VTE[20].
27
28

29
30 Men seemed to respond to statin use more favourably than females, indicating a plausible
31
32 hormonal regulation of the effect of statins. In women we did not control for hormonal
33
34 replacement therapy, which may be a confounding remedy, known to be a risk factor for
35
36 VTE[21,22] The well-known age-association in increasing the incidence of DVT and PE was
37
38 evidenced also among our patients. Also, the overall incidence of VTE in Finland is compatible
39
40 with what has been reported internationally. The protective association with incidence of VTE
41
42 among highest third tertile of HDL-LDL ratio, lowest homocysteine and CRP support earlier
43
44 results of these surrogate laboratory markers.
45
46

47
48 Several limitations must be kept in mind when evaluating results from any observational
49
50 study based on record linkage of drug information. Firstly, the comprehensive use of
51
52 prescribed drugs in this study, could not be verified with certainty, and may be subject to
53
54 misclassification. The prescription data do not contain information on drugs used in nursing
55
56
57
58
59
60

1
2
3
4
5
6
7 homes, therefore, the misclassification of exposure is more likely among the older patient
8
9 groups. Secondly, although model based adjustments using regression and IPW were applied,
10
11 it is always possible that residual confounding factors could influence the results. E.g. statin
12
13 usage may depend on variables that are not included in the statistical models; or the
14
15 statistical models used in the analysis do not properly adjust for the confounding factors. The
16
17 importance of adjusting for possible confounding effects is reflected by the large difference
18
19 between estimates obtained from the uni- and multivariate models. On the other hand, the
20
21 results based on three models with different pattern of covariates and modeling technique
22
23 remained nearly unchanged regarding the effect of current statin usage (Table 3). This
24
25 compatibility increases the credibility of the results. Also, the hospital records that are
26
27 nationally gathered may suffer from inconsistencies. Recently, these were evaluated in a
28
29 separate study which validated this form of data collection in PE, but not in DVT[23].
30
31

32 In conclusion, statin use offers protection against first ever VTE event. The elevated LDL
33
34 cholesterol, CRP and homocysteine, as reported earlier also associate with the risk of new
35
36 VTE. Statins appears as a primary prevention tool in patients with a high risk of VTE, exerting
37
38 its best effect in male population.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgement

This study was funded by University of Helsinki and The National Institute for Health and Welfare, Finland (THL).

RL, AJ and JP have no relevant disclosures to declare. JH has had previous research agreements with Janssen-Cilag, Novartis, Orion Pharma, Abbott, Novo Nordisk Farma, Pfizer, Sanofi-Aventis, Astellas, and Takeda.

Contributorship Statement

Formatted: Font: Bold

All authors have substantial contributions to the conception and design of the work and acquisition of the data. JH did analyses, all authors contributed to interpretation of data for the work

JH drafted the work, other authors revised it critically for important intellectual content.

All authors have approved the final version of the work to be published.

All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing Interests

None

Data Sharing Statement

No additional data available

Formatted: Font: Bold

References

1. Kearon C, Akl EA, Comerota AJ, *et al.* Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;**141**:e419S–94S. doi:10.1378/chest.11-2301
2. Squizzato A, Galli M, Romualdi E, *et al.* Statins, fibrates, and venous thromboembolism: a meta-analysis. *Eur Heart J* 2010;**31**:1248–56. doi:10.1093/eurheartj/ehp556
3. Glynn RJ, Danielson E, Fonseca FAH, *et al.* A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. *New England Journal of Medicine* 2009;**360**:1851–61. doi:10.1056/NEJMoa0900241
4. Biere-Rafi S, Hutten BA, Squizzato A, *et al.* Statin treatment and the risk of recurrent pulmonary embolism. *Eur Heart J* 2013;**34**:1800–6. doi:10.1093/eurheartj/ehp046
5. Khemasuwan D, Divietro ML, Tangdhanakanond K, *et al.* Statins decrease the occurrence of venous thromboembolism in patients with cancer. *Am J Med* 2010;**123**:60–5. doi:10.1016/j.amjmed.2009.05.025
6. Akkerman JWN. From low-density lipoprotein to platelet activation. *Int J Biochem Cell Biol* 2008;**40**:2374–8. doi:10.1016/j.biocel.2008.04.002
7. Aromaa A, Koskinen S. Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Helsinki, Finland: 2004. <http://www.terveys2000.fi/julkaisut/baseline.pdf>
8. Heistaro S. Methodology report : Health 2000 survey. Helsinki, Finland: : Kansanterveyslaitos 2008. <http://lib.thl.fi:2345/http://lib.thl.fi:2345/lib4/?PBFORMTYPE=01002&TITLEID=49681&SQS=1:FIN:1::6:50::HTML&PL=0>
9. Luotola K, Pietilä A, Zeller T, *et al.* Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. *Journal of Internal Medicine* 2011;**269**:322–32. doi:10.1111/j.1365-2796.2010.02294.x
10. Juonala M, Viikari JSA, Laitinen T, *et al.* Interrelations Between Brachial Endothelial Function and Carotid Intima-Media Thickness in Young Adults The Cardiovascular Risk in Young Finns Study. *Circulation* 2004;**110**:2918–23. doi:10.1161/01.CIR.0000147540.88559.00
11. Kauppi M, Impivaara O, Mäki J, *et al.* Vitamin D status and common risk factors for bone fragility as determinants of quantitative ultrasound variables in a nationally representative population sample. *Bone* 2009;**45**:119–24. doi:10.1016/j.bone.2009.03.659

Field Code Changed

Formatted: English (U.S.)

- 1
2
3
4
5
6
7 12 WHOCC - ATC/DDD Index. http://www.whooc.no/atc_ddd_index/ (accessed 11 Sep2012).
- 8
9 13 Carstensen B, Plummer M, Laara E, *et al*. *Epi: A package for statistical analysis in*
10 *epidemiology*. 2008. <http://www.pubhealth.ku.dk/bxc/Epi/>
- 11
12 14 Cole SR, Hernan MA. Constructing Inverse Probability Weights for Marginal Structural
13 Models. *Am J Epidemiol* 2008;**168**:656–64. doi:10.1093/aje/kwn164
- 14
15 15 Rahimi K, Bhala N, Kamphuisen P, *et al*. Effect of Statins on Venous Thromboembolic
16 Events: A Meta-analysis of Published and Unpublished Evidence from Randomised
17 Controlled Trials. *PLoS Med* 2012;**9**:e1001310. doi:10.1371/journal.pmed.1001310
- 18
19 16 Ridker PM, Pradhan A, MacFadyen JG, *et al*. Cardiovascular benefits and diabetes risks of
20 statin therapy in primary prevention: an analysis from the JUPITER trial. *The Lancet*
21 **11**;380:565–71. doi:10.1016/S0140-6736(12)61190-8
- 22
23 17 Westerbacka J, Yki-Järvinen H, Turpeinen A, *et al*. Inhibition of Platelet-Collagen
24 Interaction An In Vivo Action of Insulin Abolished by Insulin Resistance in Obesity.
25 *Arterioscler Thromb Vasc Biol* 2002;**22**:167–72. doi:10.1161/hq0102.101546
- 26
27 18 Psaty BM, Siscovick DS. Minimizing Bias Due to Confounding by Indication in Comparative
28 Effectiveness Research The Importance of Restriction. *JAMA* 2010;**304**:897–8.
29 doi:10.1001/jama.2010.1205
- 30
31 19 Prandoni P, Ghirarduzzi A, Prins MH, *et al*. Venous thromboembolism and the risk of
32 subsequent symptomatic atherosclerosis. *Journal of Thrombosis and Haemostasis*
33 2006;**4**:1891–6. doi:10.1111/j.1538-7836.2006.02058.x
- 34
35 20 Prandoni P, Noventa F, Milan M. Aspirin and recurrent venous thromboembolism.
36 *Phlebology* 2013;**28 Suppl 1**:99–104. doi:10.1177/0268355512475040
- 37
38 21 Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of
39 venous thrombosis: meta-analysis. *BMJ* 2001;**323**:131. doi:10.1136/bmj.323.7305.131
- 40
41 22 Shufelt CL, Bairey Merz CN. Contraceptive Hormone Use and Cardiovascular Disease.
42 *Journal of the American College of Cardiology* 2009;**53**:221–31.
43 doi:10.1016/j.jacc.2008.09.042
- 44
45 23 Casez P, Labarère J, Sevestre M-A, *et al*. ICD-10 hospital discharge diagnosis codes were
46 sensitive for identifying pulmonary embolism but not deep vein thrombosis. *Journal of*
47 *Clinical Epidemiology* 2010;**63**:790–7. doi:10.1016/j.jclinepi.2009.09.002
- 48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1 Baseline characteristics of study population

Categorical variables and usage of drugs at baseline						
Sex	male		3589	45%		
	female		4336	55%		
Blood glucose lowering drug	no		7637	96%		
	yes		288	4%		
Insulin	no		7787	98%		
	yes		138	2%		
Antithrombotic agent	no		7582	96%		
	yes		343	4%		
Antiplatelet agent	no		7764	98%		
	yes		161	2%		
Vitamin K antagonists	no		7732	98%		
	yes		193	2%		
Continuous variables at baseline LDL cholesterol (mmol/L)						
	1st Qu.	Median	Mean	3rd Qu.	SD	Missing
Age	42.0	52.0	54.7	66.0	16.1	100
Blood glucose (mmol/L)	5.0	5.3	5.6	5.7	1.3	1275
Total cholesterol (mmol/L)	5.1	5.9	5.9	6.6	1.1	1275
HDL cholesterol (mmol/L)	1.1	1.3	1.3	1.6	0.4	1275
LDL cholesterol (mmol/L)	3.1	3.8	3.8	4.5	1.2	1276
Triglycerides (mmol/L)	1.0	1.3	1.6	1.9	1.1	1275
Ratio HDL/Chol	18.0	22.0	23.0	28.0	7.4	1275
CRP (mg/L)	0.3	0.8	2.3	2.0	6.3	1694
Vitamin D3 (nmol/L)	33.0	43.0	44.9	55.0	16.9	1825
Homocysteine (µmol/L)	9.2	11.0	12.0	13.5	5.1	1825
Insulin (mU/L)	5.0	7.0	9.6	11.0	30.3	1627

Table 2. Incidence of end-point events. RR (rate ratios) with 95% confidence intervals (CI) based on univariate Poisson regression model. Laboratory measurements in tertiles "[a,b]" means that interval a-b is closed left and open right. The data on variables are collected at baseline.

Variable	P-years (1000)	Events	Incidence (1/1000)	95% CI		RR	95% CI	
Current statin usage								
no	67.78	118	1.74	1.44	2.09			
yes	11.17	18	1.61	0.95	2.55	0.93	0.56	1.52
Sex								
male	36.02	53	1.47	1.1	1.93			
female	42.93	83	1.93	1.54	2.4	1.31	0.93	1.85
Age								
(0,40]	19.92	10	0.50	0.24	0.92			
(40,50]	20.22	15	0.74	0.41	1.22	1.48	0.66	3.29
(50,60]	17.11	24	1.40	0.90	2.09	2.79	1.34	5.84
(60,70]	11.05	28	2.53	1.68	3.66	5.05	2.45	10.39
(70,Inf]	10.65	59	5.54	4.22	7.15	11.04	5.65	21.58
Insulin usage at baseline								
no	77.83	133	1.71	1.43	2.03			
yes	1.12	3	2.68	0.55	7.83	1.57	0.50	4.92
Blood glucose lowering drug								
no	76.71	124	1.62	1.34	1.93			
yes	2.24	12	5.37	2.77	9.37	3.32	1.84	6.00
Antithrombotic agent usage								
no	76.7	120	1.56	1.30	1.87			
yes	2.25	16	7.11	4.06	11.55	4.55	2.70	7.66
Antiplatelet agents usage								
no	77.87	126	1.62	1.35	1.93			
yes	1.08	10	9.27	4.44	17.05	5.73	3.01	10.91
Vitamin K antagonists usage								
no	77.7	128	1.65	1.37	1.96			
yes	1.25	8	6.42	2.77	12.66	3.90	1.91	7.97
Blood glucose (mmol/L)								
[2.4,5.1]	24.79	36	1.45	1.02	2.01			
(5.1,5.6]	23.93	31	1.30	0.88	1.84	0.89	0.55	1.44
(5.6,26.7]	18.69	48	2.57	1.89	3.40	1.77	1.15	2.72
Total cholesterol (mmol/L)								
[1.9,5.4]	23.71	36	1.52	1.06	2.10			
(5.4,6.3]	21.33	33	1.55	1.06	1.02	0.64	1.63	1.02
(6.3,11.7]	22.38	46	2.06	1.50	1.35	0.88	2.09	1.35
HDL cholesterol (mmol/L)								
[0.23,1.13]	22.39	45	2.01	1.46				

(1.13,1.45]	22.45	33	1.47	1.01	0.73	0.47	1.15	0.73
(1.45,3.41]	22.57	37	1.64	1.15	0.82	0.53	1.26	0.82
LDL cholesterol (mmol/L)								
[0,3.3]	22.56	34	1.51	1.04				
(3.3,4.2]	22.79	38	1.67	1.18	1.11	0.70	1.76	1.11
(4.2,8.8]	22.06	43	1.95	1.41	1.29	0.82	2.03	1.29
Triglycerides (mmol/L)								
[0.4,1.1]	26.16	30	1.15	0.77				
(1.1,1.7]	21.84	45	2.06	1.50	1.80	1.13	2.85	1.80
(1.7,16.6]	19.42	40	2.06	1.47	1.80	1.12	2.88	1.80
Ratio HDL/Chol								
[3,19]	23.92	48	2.01	1.48				
(19,25.7]	20.58	34	1.65	1.14	0.82	0.53	1.28	0.82
(25.7,56]	22.91	33	1.44	0.99	0.72	0.46	1.12	0.72
C-reactive protein (mg/L)								
[0,0.39]	22.26	22	0.99	0.62				
(0.39,1.41]	21.62	42	1.94	1.40	1.97	1.17	3.29	1.97
(1.41,191]	20.53	40	1.95	1.39	1.97	1.17	3.32	1.97
Vitamin D3 (nmol/L)								
[5,36]	20.55	35	1.70	1.19	2.37			
(36,50]	21.42	31	1.45	0.98	2.06	0.85	0.52	1.38
(50,134]	21.15	37	1.75	1.23	2.41	1.03	0.65	1.63
Homocysteine (µmol/L)								
[3.7,9.7]	22.15	18	0.81	0.48	1.29			
(9.7,12.5]	21.82	32	1.47	1.00	2.07	1.80	1.01	3.22
(12.5,111]	19.16	53	2.77	2.07	3.62	3.40	1.99	5.81
Insulin (mU/L)								
[1,5]	22.72	26	1.14	0.75	1.68			
(5,9]	22.67	45	1.99	1.45	2.66	1.73	1.07	2.81
(9,2200]	19.64	33	1.68	1.16	2.36	1.47	0.88	2.00

Table 3. Rate ratios (RR) with 95% confidence intervals (CI) of three Poisson regression models. Model I included only statin, age and sex as covariates. Models II and III included also Blood glucose lowering drug, Insulin usage, Vitamin K antagonists usage, and Antiplatelet agents usage as covariates. Inverse Probability Weights (IPW) Model III is based on stabilized weights for statin usage. In IPW model age and sex were in numerator, and age, sex, baseline oral antidiabetics, baseline insulin, and baseline anticoagulant usage were in denominator.

		Model I			Model II			Model III		
		RR (95% CI)			RR (95% CI)			RR, IPW (95% CI)		
Statin	no	(reference)			(reference)			(reference)		
	current	0.64	0.38	1.05	0.60	0.36	1.00	0.58	0.35	0.96
Age	under 40	(reference)			(reference)			(reference)		
	(40,50]	1.52	0.68	3.38	1.51	0.68	3.37	1.53	0.68	3.43
	(50,60]	2.99	1.42	6.26	2.91	1.39	6.10	3.20	1.53	6.70
	(60,70]	5.66	2.73	11.75	5.31	2.55	11.05	5.36	2.55	11.24
	(70,Inf]	11.68	5.94	22.95	9.92	4.99	19.74	9.93	4.95	19.92
Sex	male	(reference)			(reference)			(reference)		
	female	1.02	0.72	1.45	1.02	0.72	1.46	0.99	0.70	1.41
Blood glucose lowering drug	no	(reference)			(reference)			(reference)		
	yes	1.89	0.98	3.63	1.63	0.86	3.11	1.63	0.86	3.11
Insulin usage	no	(reference)			(reference)			(reference)		
	yes	0.72	0.21	2.45	0.72	0.25	2.13	0.72	0.25	2.13
Vitamin K antagonists	no	(reference)			(reference)			(reference)		
	yes	1.46	0.69	3.07	1.38	0.68	2.80	1.38	0.68	2.80
Antiplatelet agents	no	(reference)			(reference)			(reference)		
	yes	2.33	1.20	4.53	2.60	1.42	4.76	2.60	1.42	4.76

Table 4. Statin usage and sex, interaction model. Model included age, Blood glucose lowering drug, Insulin usage, Vitamin K antagonists usage, and Antiplatelet agents usage as covariates.

	P-years	Events	Incidence (95% CI)			RR (95% CI)		
no statin/male	30.57	50	1.64	1.21	2.16	(reference)		
statin/male	5.45	3	0.55	0.11	1.61	0.20	0.06	0.65
no statin/female	37.21	68	1.83	1.42	2.32	0.87	0.60	1.27
statin/female	5.72	15	2.62	1.47	4.33	0.75	0.41	1.38

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Statin use associates with a reduced incidence of venous thromboembolism – A population-based cohort study (b) Provide in the abstract an informative and balanced summary of what was done and what was found Done
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Done
Objectives	3	State specific objectives, including any prespecified hypotheses Done
Methods		
Study design	4	Present key elements of study design early in the paper Done
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Done
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Done (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Done
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Done
Bias	9	Describe any efforts to address potential sources of bias Done
Study size	10	Explain how the study size was arrived at Done
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Done (b) Describe any methods used to examine subgroups and interactions Done (c) Explain how missing data were addressed Done (d) If applicable, explain how loss to follow-up was addressed Done (e) Describe any sensitivity analyses Done

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Done
		(b) Give reasons for non-participation at each stage Done
		(c) Consider use of a flow diagram Not included, presented in previous papers
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Done
		(b) Indicate number of participants with missing data for each variable of interest Done
		(c) Summarise follow-up time (eg, average and total amount) Done
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Done, 95% Ci given, interaction test with p-value and X2 test.
		(b) Report category boundaries when continuous variables were categorized Done
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not done because of brevity. Easy to do if needed with data in tables.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Done
Discussion		
Key results	18	Summarise key results with reference to study objectives Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Done
Generalisability	21	Discuss the generalisability (external validity) of the study results Done. This is population based study.
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Details give, not extra funding.

*Give information separately for exposed and unexposed groups.

1 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
2 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
3 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
4 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
5 available at <http://www.strobe-statement.org>.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

The association of statin use with a reduced incidence of venous thromboembolism – A population-based cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-005862.R1
Article Type:	Research
Date Submitted by the Author:	02-Sep-2014
Complete List of Authors:	Lassila, Riitta; Medical Faculty, University of Helsinki Jula, Antti; The National Institute for Health and Welfare, Pitkaniemi, Janne; University of Helsinki, Hjelt Institute, Public Health Haukka, Jari; University of Helsinki, Hjelt Institute, Public Health
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Epidemiology
Keywords:	Thromboembolism < CARDIOLOGY, EPIDEMIOLOGY, Anticoagulation < HAEMATOLOGY

SCHOLARONE™
Manuscripts

Statin use associates with a reduced incidence of venous thromboembolism – A population-based cohort study

¹Riitta LassilaMD, PhD, ²Antti Jula, MD, PhD, ³ JannePitkäniemi, PhD,
and ³Jari Haukka, MD, PhD

¹Coagulation Disorders Unit, Department of Medicine, Division of Hematology and Laboratory Services HUSLAB and Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland

²The National Institute for Health and Welfare (THL), Finland

³Hjelt Institute, University of Helsinki, Finland

Corresponding author:

Jari Haukka
University of Helsinki, Hjelt Institute
PO Box 40, FI-00014 University of Helsinki, Finland
email: jari.haukka@helsinki.fi
tel.: +358 50 4155314
fax.: +358 09 191 27518

Keywords: venous thromboembolism, epidemiology, statins, cohort study

Word count: 2978

Abstract

Objectives: Venous thromboembolism (VTE) continues to be a frequent, medical emergency demanding condition to reach the diagnosis and initiate anticoagulation therapy. The use of statins is reported, in addition to reducing the incidence of arterial thrombosis, also to decrease both the incidence and reoccurrence of VTE. The aim of our study was to explore the association between statin usage and the incidence of new VTE at the population level during a 10-year follow-up.

Design: Population based historic cohort

Setting: The Health 2000 survey was based on a nationally representative sample.

Participants: 8028 individuals aged 30 years or over in Finland.

Primary and secondary outcome measures: The primary end-point event was the first ever hospitalization due to one of the following causes: pulmonary embolism (ICD10 I26), cerebral venous nonpyogenic thrombosis (I63.6), and venous thrombosis (I80.0-189).

Results: The preselected explanatory variables applied to Poisson regression model were statin usage (no/yes) during follow-up (2000-2011) and several baseline data (age, sex; usage of blood glucose lowering drug, vitamin K antagonists, and anti-platelet agents). We observed 136 VTE events, the incidence of 1.72 (95% CI 1.44-2.04) per 1000 person-years. Current statin usage did not associate with the incidence of VTE according to the univariate model (RR 0.93, 0.56-1.52), but when adjusted with baseline variables (age, sex, medications) the RR declined to 0.60 (0.36-1.00, $p=0.04$).

Conclusions: Statin use offers protection against first ever VTE event and appears as a primary prevention tool in patients without anticoagulation or anti-platelet medication.

Strengths of this study

- population based, no selection bias in start of follow-up
- long and complete follow-up information

Limitations of this study

- limited number of background variables and incidence events
- the comprehensive use of prescribed drugs in this study, could not be verified with certainty

Introduction

Venous thromboembolism (VTE) continues to be a frequent condition which demands medical emergency attention to reach the diagnosis and initiate anticoagulation therapy. The mortality during a few months after VTE varies between 5-20%, and the patients often have other co-morbidities, such as cardiovascular disease and cancer. The yearly incidence of VTE is 1-2/1000 inhabitants in western societies. Nowadays, the traditional heparin and vitamin K antagonist (VKA) therapy followed with the course of temporal (3-6 months) or permanent VKA can be opted with novel oral anticoagulants[1].

The decision of either continuing the anticoagulation for a few months or permanently depends on the acquired or inherited risk factor profile of the patient. This includes age above 60 years and concomitant illness, including cancer and inflammatory diseases as well as obesity, hormonal remedies and family history or severe thrombophilias (such as homozygosity of factor V Leiden or prothrombin mutation, double defects, antiphospholipid antibody syndrome), subjecting the patient to recurrent VTE. Despite the clinical evaluation the recurrence rate of VTE continues to

1
2
3 be 15-20% after an idiopathic event and around 5% after a provoked thrombosis[1]. Bleeding
4
5 tendency needs to be regularly weighted also against the risk of thrombosis recurrence, while
6
7 maintaining the anticoagulation.
8
9

10
11 The use of statins has been reported to reduce the incidence of not only the arterial thrombosis,
12
13 but also interesting data on the decline of both the incidence and reoccurrence of VTE have
14
15 emerged. Retrospective observational and case-control studies as well as experimental evidence
16
17 refer to the possibility that statins exert an antithrombotic effect also in the venous system. A
18
19 recent meta-analysis reported the association of VTE and a 20-36% protection with statin use[2]. A
20
21 primary prevention trial of VTE with rosuvastatin in a randomized placebo-controlled design
22
23 showed a 48% reduction in the incidence of VTE[3]. Moreover, statin treatment alleviated the risk
24
25 of recurrent pulmonary embolism by 50% whether the patient used long-term vitamin K
26
27 antagonist treatment or had stopped anticoagulation, as reported by a Dutch population-based
28
29 study with initially hospitalized patients[4]. Finally, statins decrease the occurrence of venous
30
31 thromboembolism even in patients with cancer[5].
32
33
34
35
36
37

38 Statins reduce the procoagulant activity of platelet membranes and downplay the signaling via LDL
39
40 receptors, which are engaged with the platelet activation[6]. Statins also enhance fibrinolysis by
41
42 reducing the plasminogen activator inhibitor-1 and triglyceride concentration. Also, other
43
44 pleiotropic and anti-inflammatory mechanisms, including dampened tissue factor expression by
45
46 monocytes, have been described which can attenuate the risk of thrombosis.
47
48
49
50

51
52 The aim of the study was to explore the association between statin usage and incidence of the
53
54 first ever VTE in Finland. Our study utilizes a nationally representative sample of 8028 persons
55
56
57
58
59
60

1
2
3 aged >30 years [7] of The Health 2000 Survey and a prospective observational pharmaco-
4
5 epidemiological design.
6
7

8 9 **Material and methods**

10 11 **Study population**

12
13
14
15
16 The Health 2000 survey was based on a nationally representative sample of 8028
17
18 individuals aged 30 years or over in Finland. To ensure that sample is representative of the
19
20 Finnish population, a two-stage stratified cluster sampling procedure was used. The baseline
21
22 data collection from study subjects took place between September 2000 and June 2001, and
23
24 consisted of an interview and a comprehensive health examination. Of the study sample 6986
25
26 subjects (87 %) were interviewed at their home or in an institution, 6354 subjects (79 %)
27
28 took part in a comprehensive health examination and 416 subjects (5%) were examined at
29
30 their home. The Health 2000 study was approved by the Ethics Committees of the National
31
32 Public Health Institute (since 2009 the National Institute for Health and Welfare) and the
33
34 Hospital District of Helsinki and Uusimaa, and the participants gave written informed
35
36 consent[7].
37
38
39
40
41

42 43 **Follow-up time and end-points**

44
45
46 The primary end-point event of this study was the first hospitalization due one of the
47
48 following causes: pulmonary embolism (ICD10 I26), cerebral infarction due to cerebral
49
50 venous nonpyogenic thrombosis (I63.6), deep vein thrombosis, including thrombophlebitis of
51
52 lower extremities (I80.0-I80.9). The information about end-points was obtained from
53
54 National Hospital Discharge Register that covers all hospitalizations in Finland starting from
55
56 1969. The 10-year follow-up was started at the beginning of Health 2000 Study and was
57
58
59
60

1
2
3 stopped at death, end of year 2011, or end-point, whichever occurred first. The data about
4
5 deaths were obtained from the Statistics Finland. There were 103 individuals with recorder
6
7 primary end-point before the start of follow-up compatible with the general prevalence of the
8
9 disease, and these subjects were excluded from the study population. Thus, the size of study
10
11 population in the start of follow-up was 7925.
12
13

14 15 **Laboratory measurements**

16
17 Venous blood samples were drawn from the antecubital vein after a minimum of 4 h fasting.
18
19 HDL cholesterol, total cholesterol, triglyceride and plasma glucose concentrations were
20
21 determined enzymatically (Roche Diagnostics, GmbH, Mannheim, Germany for HDL; Olympus
22
23 System Reagent, Hamburg, Germany for total cholesterol, triglycerides and glucose) with a
24
25 clinical chemistry analyser (Olympus, AU400, Hamburg, Germany)[8]. C-reactive protein
26
27 (CRP) concentrations were determined by a chemiluminescent immunometric assay
28
29 (Immulite, Diagnostic Products, Los Angeles, CA)[8]. LDL cholesterol was calculated with the
30
31 Friedewald formula. Plasma insulin and homocysteine concentrations were determined with
32
33 microparticle enzyme immunoassay (Abbott Laboratories, Dainabot, Tokyo, Japan)[9,10]. S-
34
35 25(OH)D concentrations were measured by radioimmunoassay (Incstar, Stillwater, MN,
36
37 USA)[11].
38
39
40
41
42
43

44 45 **Drug information**

46
47 The data about the prescribed and purchased drugs were obtained from registers of the Social
48
49 Insurance Institution. We had records of the following drugs classified by Anatomical
50
51 Therapeutic Chemical (ATC) code[12]: statins (C10AA), blood glucose lowering drugs,
52
53 excluding insulins (A10B), insulin (A10A), VKA (B01AA) , and antiplatelet agents, excluding
54
55 heparin (B01AC) and over the counter acetylsalicylic acid. Regarding statins the data included
56
57 all prescribed statins purchased during the follow-up period in 2000 – 2006 and 2008.
58
59
60

1
2
3 Because there were no data available regarding the drug amounts purchased for years 2007,
4 and 2009-2011, we calculated the mean amount of purchase based on available years and
5 adapted it for the whole follow-up period. Time dependent variable for the current statin
6 usage was determined for each individual with the prescription data using R language
7 package Epi[13]. The follow-up time of each individual with statin exposure was cut into 6-
8 month periods and the statin usage in each period was determined. For other drugs we had
9 only the number of prescriptions at the baseline year 2000, which was used to construct a
10 dichotomic variable of drug usage at baseline (no/yes).
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Statistical modeling**

27
28 We applied the Poisson regression model using end-point event as a dependent variable,
29 length of the follow-up as an offset variable, and statin usage (no/yes) during each time
30 period as time-varying explanatory variable. The following variables were used as time-
31 invariant variables measured at baseline: age (30-40, 40-50, 50-60, 60-70, over 70), sex
32 (male/female), blood glucose lowering drug usage, excluding insulins (no/yes), insulin usage
33 (no/yes), vitamin K antagonists usage (no/yes), antiplatelet agents (no/yes), blood glucose
34 (mmol/L), total cholesterol (mmol/L), HDL cholesterol (mmol/L), LDL cholesterol (mmol/L),
35 triglycerides (mmol/L), CRP (mg/L), vitamin D3 (nmol/L), homocysteine ($\mu\text{mol/L}$), and
36 insulin (mU/L). The values of the laboratory measurements were transformed to categorical
37 variables defined by tertiles. We also estimated the inverse probability weights (IPW) to fit
38 marginal structural models[14]. IPW were estimated using age and sex in the numerator, and
39 age, sex, blood glucose lowering drugs other than insulin usage, VKA usage, and use of
40 antiplatelet agent in the denominator. In order to check survivor bias we carried out
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 modeling without subjects with prevalent statin use in start of follow-up (N=460 excluded)
4
5 [15].
6
7

8 9 **Results**

10
11
12 The size of the study population was 7925, including 3589 males and 4336 females (Table 1).
13
14 We observed 136 VTE events during the follow-up with the incidence of 1.72 (95% CI 1.44-
15
16 2.04) per 1000 person-years during the mean follow-up time 10 years (Table 2). There were
17
18 64 events with the diagnosis pulmonary embolism (ICD-10 I26), one with sinus thrombosis
19
20 (I636) and 71 with deep vein thrombosis (I80.0-I80.9).
21
22
23

24
25
26 All together there were 67,532 statin prescriptions, and 2083 individuals (26% of population)
27
28 had at least one prescription. Simvastatin (ATC code C10AA01) with 54% of prescriptions
29
30 and atorvastatin (C10AA05) with 23% represented the most frequent active lipid-lowering
31
32 substances. Current statin usage that comprised 14% of all cumulated person-years, did not
33
34 associate with the incidence of VTE according to the univariate model Rate Ratio (RR) 0.93
35
36 (0.56-1.52)(Table 2). The use of oral antidiabetic drugs at the baseline was associated with a
37
38 three-fold increased incidence (RR 3.32, 1.84-6.00), but insulin usage did not show any
39
40 association. Using any antithrombotic drugs associated with higher incidence (RR 4.55, 2.70-
41
42 7.66).
43
44
45
46
47
48

49
50 Addition of more explanatory variables in the model substantially altered the association
51
52 between the statin usage and incidence (Table 3). Adjusting for sex, age, baseline oral
53
54 antidiabetic, insulin, and use of antithrombotics (Model II) reduced the RR to 0.60 (0.36-1.00).
55
56 Using IPW for the structural model (Model III) decreased the RR further to 0.58 (0.35-0.96).
57
58
59
60

1
2
3 Adjusting for the baseline laboratory measurements also decreased slightly the estimate for
4
5 statin effect, e.g. adjusting for CRP gave RR 0.43 (0.23- 0.81). However, because of the missing
6
7 laboratory measurements we do not report these results in further detail, e.g. for CRP there
8
9 were several (1694) missing values. (Table 2). Increased levels of LDL associated with an
10
11 increasing incidence of VTE, the same occurred with homocysteine.
12
13

14
15
16 In addition, we looked for the possible interactions between statin usage and age, sex, blood
17
18 glucose lowering drugs usage (excluding use of insulin), VKA and platelet aggregation
19
20 inhibitors. Interaction for sex and statin usage was significant ($\chi^2=6.310$, $df=1$, $p=0.012$).
21
22

23 Interestingly, it turned out that the incidence of VTE among the statin group for males was
24
25 quite low (RR 0.22, 0.06-0.65), but for females such an association was not obvious (RR 0.75,
26
27 0.41-1.38), upon comparing the statin usage without its usage (Table 4.).
28
29

30
31
32 In sensitivity analyses without prevalent statin users there was 115 cases in non-statin group
33
34 and 10 cases in statin group; unadjusted RR was 0.82 (0.43- 1.56) and adjusted 0.63 (0.33-
35
36 1.21).
37
38

39 40 41 Discussion

42
43 To our knowledge, this is the first report studying association between statin usage and VTE
44
45 that utilizes a nationally representative population sample. Our results during the 11 years of
46
47 prospective follow-up on the incidence of VTE are in line with the recent meta-analysis[16],
48
49 which showed the risk reduction of 0.89 (0.78-1.01) for VTE among statin users. The
50
51 JUPITER study, the largest randomized trial, including 465 events, showed 36% reduction in
52
53 VTE (RR 0.64, 0.39-1.06, $p=0.08$)[3,16]. Our study addressed the new incidence of VTE, as
54
55 the patients who previously had suffered from VTE (136/8028) were excluded from study
56
57
58
59
60

1
2
3 population. The prospective nature and large population-based design of pharmaco-
4
5 epidemiology are the strengths of our study.
6
7

8
9
10 In this freely living Finnish population sample we could demonstrate that statin use is
11
12 associated with a reduction of the incidence of VTE, including both deep vein thrombosis of
13
14 the lower extremities, pulmonary embolism and one case of cerebrovascular sinus
15
16 thrombosis. This adds to the confirmation that statins exert anticoagulant activity[2-5].
17
18 Furthermore, it supports the idea that statin therapy could be implemented to the patients
19
20 with the risk of VTE.
21
22

23
24
25 We observed that use of oral antidiabetic drugs at the baseline was associated with a three-
26
27 fold increased incidence (RR 3.32, 1.84-6.00), which refers to that insulin-resistant patients
28
29 carry a high risk of VTE, and the oral antidiabetic drugs do not seem to alleviate this risk,
30
31 while insulin may do so[18]. The positive association between antithrombotic drugs and VTE
32
33 is quite probably due to confounding by indication[19], and also the co-occurrence of
34
35 cardiovascular disease and VTE has been noted in several studies[20]. The limitation of our
36
37 study relies on the fact that over-the counter aspirin use is not controlled. This is significant,
38
39 as aspirin has been recently shown to inhibit the reoccurrence of idiopathic VTE[21].
40
41
42
43
44

45
46 Men seemed to respond to statin use more favourably than females, indicating a plausible
47
48 hormonal regulation of the effect of statins. In women we did not control for hormonal
49
50 replacement therapy, which may be a confounding remedy, known to be a risk factor for
51
52 VTE[22,23] The well-known age-association in increasing the incidence of DVT and PE was
53
54 evidenced also among our patients. Also, the overall incidence of VTE in Finland is compatible
55
56 with what has been reported internationally. The protective association with incidence of VTE
57
58
59
60

1
2
3 among highest third tertile of HDL-LDL ratio, lowest homocysteine and CRP support earlier
4
5 results of these surrogate laboratory markers.
6
7

8
9
10 Several limitations must be kept in mind when evaluating results from any observational
11
12 study based on record linkage of drug information. Firstly, the comprehensive use of
13
14 prescribed drugs in this study, could not be verified with certainty, and may be subject to
15
16 misclassification. The prescription data do not contain information on drugs used in nursing
17
18 homes, therefore, the misclassification of exposure is more likely among the older patient
19
20 groups. Secondly, although model based adjustments using regression and IPW were applied,
21
22 it is always possible that residual confounding factors could influence the results. E.g. statin
23
24 usage may depend on variables that are not included in the statistical models; or the
25
26 statistical models used in the analysis do not properly adjust for the confounding factors. The
27
28 importance of adjusting for possible confounding effects is reflected by the large difference
29
30 between estimates obtained from the uni- and multivariate models. On the other hand, the
31
32 results based on the three models with different pattern of covariates and modeling technique
33
34 remained nearly unchanged regarding the effect of current statin usage (Table 3). This
35
36 compatibility increases the credibility of the results, albeit the actual incidences are relatively
37
38 low in numbers due to the natural incidence of 1-2 cases/1000 inhabitants annually. Also, the
39
40 hospital records that are nationally gathered may suffer from inconsistencies. Recently, these
41
42 were evaluated in a separate study which validated this form of data collection in PE, but not
43
44 in DVT[24]. Thirdly, analyses without prevalent statin showed attenuated, not significant
45
46 effect, which may be due to lower effect and lower number of cases resulting wider
47
48 confidence limits.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, statin use offers protection against first ever VTE event. The elevated LDL
4
5 cholesterol, CRP and homocysteine, as reported earlier also associate with the risk of new
6
7 VTE. Statins appears as a primary prevention tool in patients with a high risk of VTE, exerting
8
9 its best effect in male population.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Acknowledgement

All authors have substantially contributed to conception and design, acquisition of data, and analysis and interpretation of data; RL and JH have drafted the article, and AJ and JP have revised it critically for important intellectual content; all authors have finally approved the version to be published. RL, AJ and JP have no relevant disclosures to declare. JH has had previous research agreements with Janssen-Cilag, Novartis, Orion Pharma, Abbott, Novo Nordisk Farma, Pfizer, Sanofi-Aventis, Astellas, and Takeda. This study was funded by University of Helsinki and The National Institute for Health and Welfare, Finland (THL). No data sharing is possible because of data protection.

Contributorship Statement

All authors have substantial contributions to the conception and design of the work and acquisition of the data. JH did analyses, all authors contributed to interpretation of data for the work.

JH drafted the work, other authors revised it critically for important intellectual content.

All authors have approved the final version of the work to be published.

All authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Competing Interests

None

Data Sharing Statement

No additional data available

References

- 1 Kearon C, Akl EA, Comerota AJ, *et al.* Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;**141**:e419S–94S. doi:10.1378/chest.11-2301
- 2 Squizzato A, Galli M, Romualdi E, *et al.* Statins, fibrates, and venous thromboembolism: a meta-analysis. *Eur Heart J* 2010;**31**:1248–56. doi:10.1093/eurheartj/ehp556
- 3 Glynn RJ, Danielson E, Fonseca FAH, *et al.* A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. *New England Journal of Medicine* 2009;**360**:1851–61. doi:10.1056/NEJMoa0900241
- 4 Biere-Rafi S, Hutten BA, Squizzato A, *et al.* Statin treatment and the risk of recurrent pulmonary embolism. *Eur Heart J* 2013;**34**:1800–6. doi:10.1093/eurheartj/ehp046
- 5 Khemasuwan D, Divietro ML, Tangdhanakanond K, *et al.* Statins decrease the occurrence of venous thromboembolism in patients with cancer. *Am J Med* 2010;**123**:60–5. doi:10.1016/j.amjmed.2009.05.025
- 6 Akkerman JWN. From low-density lipoprotein to platelet activation. *Int J Biochem Cell Biol* 2008;**40**:2374–8. doi:10.1016/j.biocel.2008.04.002
- 7 Aromaa A, Koskinen S. Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Helsinki, Finland: 2004. [http://www.terveys2000.fi/julkaisut/baseline.pdf](http://www terveys2000.fi/julkaisut/baseline.pdf)
- 8 Heistaro S. Methodology report : Health 2000 survey. Helsinki, Finland: : Kansanterveyslaitos 2008. <http://lib.thl.fi:2345/http://lib.thl.fi:2345/lib4/?PBFORMTYPE=01002&TITLEID=49681&SQS=1:FIN:1::6:50::HTML&PL=0>
- 9 Luotola K, Pietilä A, Zeller T, *et al.* Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. *Journal of Internal Medicine* 2011;**269**:322–32. doi:10.1111/j.1365-2796.2010.02294.x
- 10 Juonala M, Viikari JSA, Laitinen T, *et al.* Interrelations Between Brachial Endothelial Function and Carotid Intima-Media Thickness in Young Adults The Cardiovascular Risk in Young Finns Study. *Circulation* 2004;**110**:2918–23. doi:10.1161/01.CIR.0000147540.88559.00
- 11 Kauppi M, Impivaara O, Mäki J, *et al.* Vitamin D status and common risk factors for bone fragility as determinants of quantitative ultrasound variables in a nationally representative population sample. *Bone* 2009;**45**:119–24. doi:10.1016/j.bone.2009.03.659

- 1
2
3 12 WHOCC - ATC/DDD Index. http://www.whocc.no/atc_ddd_index/ (accessed 11 Sep2012).
- 4
5 13 Carstensen B, Plummer M, Laara E, *et al.* *Epi: A package for statistical analysis in*
6 *epidemiology*. 2008. <http://www.pubhealth.ku.dk/bxc/Epi/>
- 7
8 14 Cole SR, Hernan MA. Constructing Inverse Probability Weights for Marginal Structural
9 Models. *Am J Epidemiol* 2008;**168**:656–64. doi:10.1093/aje/kwn164
- 10
11 15 Danaei G, Tavakkoli M, Hernán MA. Bias in Observational Studies of Prevalent Users:
12 Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins. *Am J*
13 *Epidemiol* 2012;**kwr301**. doi:10.1093/aje/kwr301
- 14
15 16 Rahimi K, Bhala N, Kamphuisen P, *et al.* Effect of Statins on Venous Thromboembolic
16 Events: A Meta-analysis of Published and Unpublished Evidence from Randomised
17 Controlled Trials. *PLoS Med* 2012;**9**:e1001310. doi:10.1371/journal.pmed.1001310
- 18
19 17 Ridker PM, Pradhan A, MacFadyen JG, *et al.* Cardiovascular benefits and diabetes risks of
20 statin therapy in primary prevention: an analysis from the JUPITER trial. *The Lancet*
21 **11**;**380**:565–71. doi:10.1016/S0140-6736(12)61190-8
- 22
23 18 Westerbacka J, Yki-Järvinen H, Turpeinen A, *et al.* Inhibition of Platelet-Collagen
24 Interaction An In Vivo Action of Insulin Abolished by Insulin Resistance in Obesity.
25 *Arterioscler Thromb Vasc Biol* 2002;**22**:167–72. doi:10.1161/hq0102.101546
- 26
27 19 Psaty BM, Siscovick DS. Minimizing Bias Due to Confounding by Indication in Comparative
28 Effectiveness Research The Importance of Restriction. *JAMA* 2010;**304**:897–8.
29 doi:10.1001/jama.2010.1205
- 30
31 20 Prandoni P, Ghirarduzzi A, Prins MH, *et al.* Venous thromboembolism and the risk of
32 subsequent symptomatic atherosclerosis. *Journal of Thrombosis and Haemostasis*
33 2006;**4**:1891–6. doi:10.1111/j.1538-7836.2006.02058.x
- 34
35 21 Prandoni P, Noventa F, Milan M. Aspirin and recurrent venous thromboembolism.
36 *Phlebology* 2013;**28 Suppl 1**:99–104. doi:10.1177/0268355512475040
- 37
38 22 Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of
39 venous thrombosis: meta-analysis. *BMJ* 2001;**323**:131. doi:10.1136/bmj.323.7305.131
- 40
41 23 Shufelt CL, Bairey Merz CN. Contraceptive Hormone Use and Cardiovascular Disease.
42 *Journal of the American College of Cardiology* 2009;**53**:221–31.
43 doi:10.1016/j.jacc.2008.09.042
- 44
45 24 Casez P, Labarère J, Sevestre M-A, *et al.* ICD-10 hospital discharge diagnosis codes were
46 sensitive for identifying pulmonary embolism but not deep vein thrombosis. *Journal of*
47 *Clinical Epidemiology* 2010;**63**:790–7. doi:10.1016/j.jclinepi.2009.09.002
- 48
49
50
51
52
53
54
55
56
57
58
59
60

Tables

Table 1 Baseline characteristics of study population

Categorical variables and usage of drugs at baseline							
Sex	male		3589	45%			
	female		4336	55%			
Blood glucose lowering drug	no		7637	96%			
	yes		288	4%			
Insulin	no		7787	98%			
	yes		138	2%			
Antithrombotic agent	no		7582	96%			
	yes		343	4%			
Antiplatelet agent	no		7764	98%			
	yes		161	2%			
Vitamin K antagonists	no		7732	98%			
	yes		193	2%			
Continuous variables at baseline LDL cholesterol (mmol/L)							
		1st Qu.	Median	Mean	3rd Qu.	SD	Missing
	Age	42.0	52.0	54.7	66.0	16.1	100
	Blood glucose (mmol/L)	5.0	5.3	5.6	5.7	1.3	1275
	Total cholesterol (mmol/L)	5.1	5.9	5.9	6.6	1.1	1275
	HDL cholesterol (mmol/L)	1.1	1.3	1.3	1.6	0.4	1275
	LDL cholesterol (mmol/L)	3.1	3.8	3.8	4.5	1.2	1276
	Triglycerides (mmol/L)	1.0	1.3	1.6	1.9	1.1	1275
	Ratio HDL/Chol	18.0	22.0	23.0	28.0	7.4	1275
	CRP (mg/L)	0.3	0.8	2.3	2.0	6.3	1694
	Vitamin D3 (nmol/L)	33.0	43.0	44.9	55.0	16.9	1825
	Homocysteine (µmol/L)	9.2	11.0	12.0	13.5	5.1	1825
	Insulin (mU/L)	5.0	7.0	9.6	11.0	30.3	1627

Table 2. Incidence of end-point events. RR (rate ratios) with 95% confidence intervals (CI) based on univariate Poisson regression model. Laboratory measurements in tertiles "[a,b]" means that interval a-b is closed left and open right. The data on variables are collected at baseline.

Variable	P-years (1000)	Events	Incidence (1/1000)	95% CI		RR	95% CI	
Current statin usage								
no	67.78	118	1.74	1.44	2.09			
yes	11.17	18	1.61	0.95	2.55	0.93	0.56	1.52
Sex								
male	36.02	53	1.47	1.1	1.93			
female	42.93	83	1.93	1.54	2.4	1.31	0.93	1.85
Age								
(0,40]	19.92	10	0.50	0.24	0.92			
(40,50]	20.22	15	0.74	0.41	1.22	1.48	0.66	3.29
(50,60]	17.11	24	1.40	0.90	2.09	2.79	1.34	5.84
(60,70]	11.05	28	2.53	1.68	3.66	5.05	2.45	10.39
(70,Inf]	10.65	59	5.54	4.22	7.15	11.04	5.65	21.58
Insulin usage at baseline								
no	77.83	133	1.71	1.43	2.03			
yes	1.12	3	2.68	0.55	7.83	1.57	0.50	4.92
Blood glucose lowering drug								
no	76.71	124	1.62	1.34	1.93			
yes	2.24	12	5.37	2.77	9.37	3.32	1.84	6.00
Antithrombotic agent usage								
no	76.7	120	1.56	1.30	1.87			
yes	2.25	16	7.11	4.06	11.55	4.55	2.70	7.66
Antiplatelet agents usage								
no	77.87	126	1.62	1.35	1.93			
yes	1.08	10	9.27	4.44	17.05	5.73	3.01	10.91
Vitamin K antagonists usage								
no	77.7	128	1.65	1.37	1.96			
yes	1.25	8	6.42	2.77	12.66	3.90	1.91	7.97
Blood glucose (mmol/L)								
[2.4,5.1]	24.79	36	1.45	1.02	2.01			
(5.1,5.6]	23.93	31	1.30	0.88	1.84	0.89	0.55	1.44
(5.6,26.7]	18.69	48	2.57	1.89	3.40	1.77	1.15	2.72
Total cholesterol (mmol/L)								
[1.9,5.4]	23.71	36	1.52	1.06	2.10			
(5.4,6.3]	21.33	33	1.55	1.06	1.02	0.64	1.63	1.02
(6.3,11.7]	22.38	46	2.06	1.50	1.35	0.88	2.09	1.35

HDL cholesterol (mmol/L)									
[0.23,1.13]	22.39	45	2.01	1.46					
(1.13,1.45]	22.45	33	1.47	1.01	0.73	0.47	1.15	0.73	
(1.45,3.41]	22.57	37	1.64	1.15	0.82	0.53	1.26	0.82	
LDL cholesterol (mmol/L)									
[0,3.3]	22.56	34	1.51	1.04					
(3.3,4.2]	22.79	38	1.67	1.18	1.11	0.70	1.76	1.11	
(4.2,8.8]	22.06	43	1.95	1.41	1.29	0.82	2.03	1.29	
Triglycerides (mmol/L)									
[0.4,1.1]	26.16	30	1.15	0.77					
(1.1,1.7]	21.84	45	2.06	1.50	1.80	1.13	2.85	1.80	
(1.7,16.6]	19.42	40	2.06	1.47	1.80	1.12	2.88	1.80	
Ratio HDL/Chol									
[3,19]	23.92	48	2.01	1.48					
(19,25.7]	20.58	34	1.65	1.14	0.82	0.53	1.28	0.82	
(25.7,56]	22.91	33	1.44	0.99	0.72	0.46	1.12	0.72	
C-reactive protein (mg/L)									
[0,0.39]	22.26	22	0.99	0.62					
(0.39,1.41]	21.62	42	1.94	1.40	1.97	1.17	3.29	1.97	
(1.41,191]	20.53	40	1.95	1.39	1.97	1.17	3.32	1.97	
Vitamin D3 (nmol/L)									
[5,36]	20.55	35	1.70	1.19	2.37				
(36,50]	21.42	31	1.45	0.98	2.06	0.85	0.52	1.38	
(50,134]	21.15	37	1.75	1.23	2.41	1.03	0.65	1.63	
Homocysteine (µmol/L)									
[3.7,9.7]	22.15	18	0.81	0.48	1.29				
(9.7,12.5]	21.82	32	1.47	1.00	2.07	1.80	1.01	3.22	
(12.5,111]	19.16	53	2.77	2.07	3.62	3.40	1.99	5.81	
Insulin (mU/L)									
[1,5]	22.72	26	1.14	0.75	1.68				
(5,9]	22.67	45	1.99	1.45	2.66	1.73	1.07	2.81	
(9,2200]	19.64	33	1.68	1.16	2.36	1.47	0.88	2.00	

Table 3. Rate ratios (RR) with 95% confidence intervals (CI) of three Poisson regression models. Model I included only statin, age and sex as covariates. Models II and III included also Blood glucose lowering drug, Insulin usage, Vitamin K antagonists usage, and Antiplatelet agents usage as covariates. Inverse Probability Weights (IPW) Model III is based on stabilized weights for statin usage. In IPW model age and sex were in numerator, and age, sex, baseline oral antidiabetics, baseline insulin, and baseline anticoagulant usage were in denominator.

		Model I			Model II			Model III		
		RR (95% CI)			RR (95% CI)			RR, IPW (95% CI)		
Statin	no	(reference)			(reference)			(reference)		
	current	0.64	0.38	1.05	0.60	0.36	1.00	0.58	0.35	0.96
Age	under 40	(reference)			(reference)			(reference)		
	(40,50]	1.52	0.68	3.38	1.51	0.68	3.37	1.53	0.68	3.43
	(50,60]	2.99	1.42	6.26	2.91	1.39	6.10	3.20	1.53	6.70
	(60,70]	5.66	2.73	11.75	5.31	2.55	11.05	5.36	2.55	11.24
	(70,Inf]	11.68	5.94	22.95	9.92	4.99	19.74	9.93	4.95	19.92
Sex	male	(reference)			(reference)			(reference)		
	female	1.02	0.72	1.45	1.02	0.72	1.46	0.99	0.70	1.41
Blood glucose lowering drug	no	(reference)			(reference)			(reference)		
	yes	1.89	0.98	3.63	1.63	0.86	3.11	1.63	0.86	3.11
Insulin usage	no	(reference)			(reference)			(reference)		
	yes	0.72	0.21	2.45	0.72	0.25	2.13	0.72	0.25	2.13
Vitamin K antagonists	no	(reference)			(reference)			(reference)		
	yes	1.46	0.69	3.07	1.38	0.68	2.80	1.38	0.68	2.80
Antiplatelet agents	no	(reference)			(reference)			(reference)		
	yes	2.33	1.20	4.53	2.60	1.42	4.76	2.60	1.42	4.76

Table 4. Statin usage and sex, interaction model. Model included age, Blood glucose lowering drug, Insulin usage, Vitamin K antagonists usage, and Antiplatelet agents usage as covariates.

	P-years	Events	Incidence (95% CI)			RR (95% CI)		
no statin/male	30.57	50	1.64	1.21	2.16	(reference)		
statin/male	5.45	3	0.55	0.11	1.61	0.20	0.06	0.65
no statin/female	37.21	68	1.83	1.42	2.32	0.87	0.60	1.27
statin/female	5.72	15	2.62	1.47	4.33	0.75	0.41	1.38

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statin use associates with a reduced incidence of venous thromboembolism – A population-based cohort study

¹Riitta LassilaMD, PhD, ²Antti Jula, MD, PhD, ³ JannePitkaniemi, PhD,
and ³Jari Haukka, MD, PhD

¹Coagulation Disorders Unit, Department of Medicine, Division of Hematology and Laboratory Services HUSLAB and Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland

²The National Institute for Health and Welfare (THL), Finland

³Hjelt Institute, University of Helsinki, Finland

Corresponding author:

Jari Haukka
University of Helsinki, Hjelt Institute
PO Box 40, FI-00014 University of Helsinki, Finland
email: jari.haukka@helsinki.fi
tel.: +358 50 4155314
fax.: +358 09 191 27518

Keywords: venous thromboembolism, epidemiology, statins, cohort study

Word count: 2978

Abstract

Objectives: Venous thromboembolism (VTE) continues to be a frequent, medical emergency demanding condition to reach the diagnosis and initiate anticoagulation therapy. The use of statins is reported, in addition to reducing the incidence of arterial thrombosis, also to decrease both the incidence and reoccurrence of VTE. The aim of our study **is was** to explore the association between statin usage and the incidence of new VTE at the population level during a 10-year follow-up.

Formatted: Highlight

Design: Population based historic cohort

Setting: The Health 2000 survey was based on a nationally representative sample.

Participants: 8028 individuals aged 30 years or over in Finland.

Primary and secondary outcome measures: The primary end-point event was the first ever hospitalization due to one of the following causes: pulmonary embolism (ICD10 I26), cerebral venous nonpyogenic thrombosis (I63.6), **and venous thrombosis phlebitis and thrombophlebitis of superficial vessels of lower extremities (I180.0-180.9189).**

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Results: The preselected explanatory variables applied to Poisson regression model were statin usage (no/yes) during follow-up (2000-2011) and several baseline data (age, sex; usage of blood glucose lowering drug, vitamin K antagonists, and anti-platelet agents). We observed 136 VTE events, the incidence of 1.72 (95% CI 1.44-2.04) per 1000 person-years. Current statin usage did not associate with the incidence of VTE according to the univariate model (RR 0.93, 0.56-1.52), but when adjusted with baseline variables (age, sex, medications) the RR declined to 0.60 (0.36-1.00, p= 0.04).

Conclusions: Statin use offers protection against first ever VTE event and appears as a primary prevention tool in patients without anticoagulation or anti-platelet medication.

Strengths of this study

- population based, no selection bias in start of follow-up
- long and complete follow-up information

Limitations of this study

- limited number of background variables and incidence events
- the comprehensive use of prescribed drugs in this study, could not be verified with certainty

Formatted: Highlight

Formatted: Highlight

Introduction

Venous thromboembolism (VTE) continues to be a frequent condition which demands medical emergency attention to reach the diagnosis and initiate anticoagulation therapy. The mortality during a few months after VTE varies between 5-20%, and the patients often have other co-morbidities, such as cardiovascular disease and cancer. The yearly incidence of VTE is 1-2/1000 inhabitants in western societies. Nowadays, the traditional heparin and vitamin K antagonist (VKA) therapy followed with the course of temporal (3-6 months) or permanent VKA can be opted with novel oral anticoagulants[1].

The decision of either continuing the anticoagulation for a few months or permanently depends on the acquired or inherited risk factor profile of the patient. This includes age above 60 years and concomitant illness, including cancer and inflammatory diseases as well as obesity, hormonal remedies and family history or severe thrombophilias (such as homozygosity of factor V Leiden or

1
2
3
4
5
6
7 prothrombin mutation, double defects, antiphospholipid antibody syndrome), subjecting the
8 patient to recurrent VTE. Despite the clinical evaluation the recurrence rate of VTE continues to
9 be 15-20% after an idiopathic event and around 5% after a provoked thrombosis[1]. Bleeding
10 tendency needs to be regularly weighted also against the risk of thrombosis recurrence, while
11 maintaining the anticoagulation.
12
13
14
15

16
17
18 The use of statins has been reported to reduce the incidence of not only the arterial thrombosis,
19 but also interesting data on the decline of both the incidence and reoccurrence of VTE have
20 emerged. Retrospective observational and case-control studies as well as experimental evidence
21 refer to the possibility that statins exert an antithrombotic effect also in the venous system. A
22 recent meta-analysis reported the association of VTE and a 20-36% protection with statin use-[2].
23
24
25

26 | recent meta-analysis reported the association of VTE and a 20-36% protection with statin use-[2].
27
28 A primary prevention trial of VTE with rosuvastatin in a randomized placebo-controlled design
29 showed a 48% reduction in the incidence of VTE[3]. Moreover, statin treatment alleviated the risk
30 of recurrent pulmonary embolism by 50% whether the patient used long-term vitamin K
31 antagonist treatment or had stopped anticoagulation, as reported by a Dutch population-based
32 study with initially hospitalized patients[4]. Finally, statins decrease the occurrence of venous
33 thromboembolism even in patients with cancer[5].
34
35
36
37
38
39
40

Field Code Changed

41 Statins reduce the procoagulant activity of platelet membranes and downplay the signaling via LDL
42 receptors, which are engaged with the platelet activation[6]. Statins also enhance fibrinolysis by
43 reducing the plasminogen activator inhibitor-1 and triglyceride concentration. Also, other
44 pleiotropic and anti-inflammatory mechanisms, including dampened tissue factor expression by
45 monocytes, have been described which can attenuate the risk of thrombosis.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 The aim of the study **was** to explore the association between statin usage and incidence of the
8 first ever VTE in Finland. Our study utilizes a nationally representative sample of 8028 persons
9 aged >30 years [7] of The Health 2000 Survey and a prospective observational pharmaco-
10 epidemiological design.
11
12
13

Formatted: Highlight

14 15 16 17 **Material and methods**

18 19 20 21 **Study population**

22 The Health 2000 survey was based on a nationally representative sample of 8028
23 individuals aged 30 years or over in Finland. To ensure that sample is representative of the
24 Finnish population, a two-stage stratified cluster sampling procedure was used. The baseline
25 data collection from study subjects took place between September 2000 and June 2001, and
26 consisted of an interview and a comprehensive health examination. Of the study sample 6986
27 subjects (87 %) were interviewed at their home or in an institution, 6354 subjects (79 %)
28 took part in a comprehensive health examination and 416 subjects (5%) were examined at
29 their home. The Health 2000 study was approved by the Ethics Committees of the National
30 Public Health Institute (since 2009 the National Institute for Health and Welfare) and the
31 Hospital District of Helsinki and Uusimaa, and the participants gave written informed
32 consent[7].
33
34
35
36
37
38
39
40
41
42
43

44 45 **Follow-up time and end-points**

46
47 The primary end-point event of this study was the first hospitalization due one of the
48 following causes: pulmonary embolism (ICD10 I26), cerebral infarction due to cerebral
49 venous nonpyogenic thrombosis (I63.6), **phlebitis and thrombophlebitis of superficial**
50 **vessels deep vein thrombosis, including thrombophlebitis of lower extremities (I480.0-180.9).**
51
52
53
54
55
56
57
58
59
60

Formatted: Highlight

Comment [LR1]: 189?

Formatted: Highlight

Formatted: Highlight

1
2
3
4
5
6
7 The information about end-points was obtained from National Hospital Discharge Register
8 that covers all hospitalizations in Finland starting from 1969. The 10-year follow-up was
9 started at the beginning of Health 2000 Study and was stopped at death, end of year 2011, or
10 end-point, whichever occurred first. The data about deaths were obtained from the Statistics
11 Finland. There were 103 individuals with recorder primary end-point before the start of
12 follow-up compatible with the general prevalence of the disease, and these subjects were
13 excluded from the study population. Thus, the size of study population in the start of follow-
14 up was 7925.
15
16
17
18
19
20
21
22

23 **Laboratory measurements**

24
25 Venous blood samples were drawn from the antecubital vein after a minimum of 4 h fasting.
26
27 HDL cholesterol, total cholesterol, triglyceride and plasma glucose concentrations were
28 determined enzymatically (Roche Diagnostics, GmbH, Mannheim, Germany for HDL; Olympus
29 System Reagent, Hamburg, Germany for total cholesterol, triglycerides and glucose) with a
30 clinical chemistry analyser (Olympus, AU400, Hamburg, Germany)[8]. C-reactive protein
31 (CRP) concentrations were determined by a chemiluminescent immunometric assay
32 (Immulite, Diagnostic Products, Los Angeles, CA)[8]. LDL cholesterol was calculated with the
33 Friedewald formula. Plasma insulin and homocysteine concentrations were determined with
34 microparticle enzyme immunoassay (Abbott Laboratories, Dainabot, Tokyo, Japan)[9,10]. S-
35 25(OH)D concentrations were measured by radioimmunoassay (Incstar, Stillwater, MN,
36 USA)[11].
37
38
39
40
41
42
43
44
45
46
47

48 **Drug information**

49
50 The data about the prescribed and purchased drugs were obtained from registers of the Social
51 Insurance Institution. We had records of the following drugs classified by Anatomical
52 Therapeutic Chemical (ATC) code[12]: statins (C10AA), blood glucose lowering drugs,
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 excluding insulins (A10B), insulin (A10A), VKA (B01AA) , and antiplatelet agents, excluding
8
9 heparin (B01AC) and over the counter acetylsalicylic acid. Regarding statins the data included
10
11 all prescribed statins purchased during the follow-up period in 2000 – 2006 and 2008.
12
13 Because there were no data available regarding the drug amounts purchased for years 2007,
14
15 and 2009-2011, we calculated the mean amount of purchase based on available years and
16
17 adapted it for the whole follow-up period. Time dependent variable for the current statin
18
19 usage was determined for each individual with the prescription data using R language
20
21 package Epi[13]. The follow-up time of each individual with statin exposure was cut into 6-
22
23 month periods and the statin usage in each period was determined. For other drugs we had
24
25 only the number of prescriptions at the baseline year 2000, which was used to construct a
26
27 dichotomic variable of drug usage at baseline (no/yes).
28
29
30
31
32

33 **Statistical modeling**

34
35 We applied the Poisson regression model using end-point event as a dependent variable,
36
37 length of the follow-up as an offset variable, and statin usage (no/yes) during each time
38
39 period as time-varying explanatory variable. The following variables were used as time-
40
41 invariant variables measured at baseline: age (30-40, 40-50, 50-60, 60-70, over 70), sex
42
43 (male/female), blood glucose lowering drug usage, excluding insulins (no/yes), insulin usage
44
45 (no/yes), vitamin K antagonists usage (no/yes) , antiplatelet agents (no/yes) , blood glucose
46
47 (mmol/L), total cholesterol (mmol/L), HDL cholesterol (mmol/L), LDL cholesterol (mmol/L),
48
49 triglycerides (mmol/L), CRP (mg/L), vitamin D3 (nmol/L), homocysteine (μ mol/L), and
50
51 insulin (mU/L). The values of the laboratory measurements were transformed to categorical
52
53 variables defined by tertiles. We also estimated the inverse probability weights (IPW) to fit
54
55 marginal structural models[14]. IPW were estimated using age and sex in the numerator, and
56
57
58
59
60

1
2
3
4
5
6
7 age, sex, blood glucose lowering drugs other than insulin usage, VKA usage, and use of
8
9 antiplatelet agent in the denominator. [In order to check survivor bias we carried out](#)
10 [modeling without subjects with prevalent statin use in start of follow-up \(N=460 excluded\)](#)
11 [\[15\]](#).
12
13
14

15 16 17 Results

18
19 The size of the study population was 7925, including 3589 males and 4336 females (Table 1).
20
21 We observed 136 VTE events during the follow-up with the incidence of 1.72 (95% CI 1.44-
22 2.04) per 1000 person-years during the mean follow-up time 10 years (Table 2). There were
23
24 64 events with the diagnosis pulmonary embolism (ICD-10 I26), one with sinus thrombosis
25
26 (I636) and 71 with deep vein thrombosis (~~1.80(1.80,0.0-1.80,0.9)~~).
27
28
29
30

31 All together there were 67,532 statin prescriptions, and 2083 individuals (26% of population)
32
33 had at least one prescription. Simvastatin (ATC code C10AA01) with 54% of prescriptions
34
35 and atorvastatin (C10AA05) with 23% represented the most frequent active lipid-lowering
36
37 substances. Current statin usage that comprised 14% of all cumulated person-years, did not
38
39 associate with the incidence of VTE according to the univariate model Rate Ratio (RR) 0.93
40
41 (0.56-1.52)(Table 2). The use of oral antidiabetic drugs at the baseline was associated with a
42
43 three-fold increased incidence (RR 3.32, 1.84-6.00), but insulin usage did not show any
44
45 association. Using any antithrombotic drugs associated with higher incidence (RR 4.55, 2.70-
46
47 7.66).
48
49

50 Addition of more explanatory variables in the model substantially altered the association
51
52 between the statin usage and incidence (Table 3). Adjusting for sex, age, baseline oral
53
54
55
56
57
58
59
60

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

1
2
3
4
5
6
7 antidiabetic, insulin, and use of antithrombotics (Model II) reduced the RR to 0.60 (0.36-1.00).
8
9 Using IPW for the structural model (Model III) decreased the RR further to 0.58 (0.35-0.96).
10
11 Adjusting for the baseline laboratory measurements also decreased slightly the estimate for
12
13 statin effect, e.g. adjusting for CRP gave RR 0.43 (0.23- 0.81). However, because of the missing
14
15 laboratory measurements we do not report these results in further detail, e.g. for CRP there
16
17 were several (1694) missing values. (Table 2). Increased levels of LDL associated with an
18
19 increasing incidence of VTE, the same occurred with homocysteine.

Comment [LR2]: Kannattaisiko tämä paljastaa jo metodeissa ja kertoo jotakin syistä kun jaamasivat noista muista puuttuvista datoista

20
21
22 In addition, we looked for the possible interactions between statin usage and age, sex, blood
23
24 glucose lowering drugs usage (excluding use of insulin), VKA and platelet aggregation
25
26 inhibitors. Interaction for sex and statin usage was significant ($\chi^2=6.310$, $df=1$, $p=0.012$).
27
28 Interestingly, it turned out that the incidence of VTE among the statin group for males was
29
30 quite low (RR 0.22, 0.06-0.65), but for females such an association was not obvious (RR 0.75,
31
32 0.41-1.38), upon comparing the statin usage without its usage (Table 4.).

33
34
35
36 [In sensitivity analyses without prevalent statin users there was 115 cases in non-statin group](#)
37
38 [and 10 cases in statin group: unadjusted RR was 0.82 \(0.43- 1.56\) and adjusted 0.63 \(0.33-](#)
39
40 [1.21\).](#)

41 42 43 Discussion

44
45 To our knowledge, this is the first report studying association between statin usage and VTE
46
47 that utilizes a nationally representative population sample. Our results during the 11 years of
48
49 prospective follow-up on the incidence of VTE are in line with the recent meta-
50
51 analysis[16][15], which showed the risk reduction of 0.89 (0.78-1.01) for VTE among statin
52
53 users. The JUPITER study, the largest meta-analysis of trials randomized trial, including 465
54
55
56
57
58
59
60

Formatted: Highlight

1
2
3
4
5
6
7 events, showed 36% reduction in VTE (RR 0.64, 0.39–1.06, p=0.08)^[3,16]. Our study
8 addressed the new incidence of VTE, as the patients who previously had suffered from VTE
9 (136/8028) were excluded from study population. The prospective nature and large
10 population-based design of pharmaco-epidemiology are the strengths of our study.
11
12
13
14

Formatted: Highlight

15
16
17 In this freely living Finnish population sample we could demonstrate that statin use is
18 associated with a reduction of the incidence of VTE, including both deep vein thrombosis of
19 the lower extremities, pulmonary embolism and one case of cerebrovascular sinus
20 thrombosis. This adds to the confirmation that statins exert anticoagulant activity^[2–5].
21
22
23
24 Furthermore, it supports the idea that statin therapy could be implemented to the patients
25 with the risk of VTE.
26
27
28
29

30 We observed that use of oral antidiabetic drugs at the baseline was associated with a three-
31 fold increased incidence (RR 3.32, 1.84–6.00), which refers to that insulin-resistant patients
32 carry a high risk of VTE, and the oral antidiabetic drugs do not seem to alleviate this risk,
33 while insulin may do so^[18,17]. The positive association between antithrombotic drugs and
34 VTE is quite probably due to confounding by indication^[19,18], and also the co-occurrence of
35 cardiovascular disease and VTE has been noted in several studies^[20,19]. The limitation of
36 our study relies on the fact that over-the counter aspirin use is not controlled. This is
37 significant, as aspirin has been recently shown to inhibit the reoccurrence of idiopathic
38 VTE^[21,20].
39
40
41
42
43
44
45
46
47
48

49 Men seemed to respond to statin use more favourably than females, indicating a plausible
50 hormonal regulation of the effect of statins. In women we did not control for hormonal
51 replacement therapy, which may be a confounding remedy, known to be a risk factor for
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 VTE^[22,23]^[21,22] The well-known age-association in increasing the incidence of DVT and PE
8
9 was evidenced also among our patients. Also, the overall incidence of VTE in Finland is
10
11 compatible with what has been reported internationally. The protective association with
12
13 incidence of VTE among highest third tertile of HDL-LDL ratio, lowest homocysteine and CRP
14
15 support earlier results of these surrogate laboratory markers.

16
17
18 Several limitations must be kept in mind when evaluating results from any observational
19
20 study based on record linkage of drug information. Firstly, the comprehensive use of
21
22 prescribed drugs in this study, could not be verified with certainty, and may be subject to
23
24 misclassification. The prescription data do not contain information on drugs used in nursing
25
26 homes, therefore, the misclassification of exposure is more likely among the older patient
27
28 groups. Secondly, although model based adjustments using regression and IPW were applied,
29
30 it is always possible that residual confounding factors could influence the results. E.g. statin
31
32 usage may depend on variables that are not included in the statistical models; or the
33
34 statistical models used in the analysis do not properly adjust for the confounding factors. The
35
36 importance of adjusting for possible confounding effects is reflected by the large difference
37
38 between estimates obtained from the uni- and multivariate models. On the other hand, the
39
40 results based on **the** three models with different pattern of covariates and modeling technique
41
42 remained nearly unchanged regarding the effect of current statin usage (Table 3). This
43
44 compatibility increases the credibility of the results. **albeit the actual incidences are relatively**
45
46 **low in numbers due to the natural incidence of 1-2 cases/1000 inhabitants annually.** Also, the
47
48 hospital records that are nationally gathered may suffer from inconsistencies. Recently, these
49
50 were evaluated in a separate study which validated this form of data collection in PE, but not
51
52 in DVT^[24]^[23]. Thirdly, analyses without prevalent statin showed attenuated, not significant

Formatted: Highlight

Formatted: Highlight

1
2
3
4
5
6
7 [effect, which may be due to lower effect and lower number of cases resulting wider](#)
8 [confidence limits.](#)
9

10
11
12
13
14
15 In conclusion, statin use offers protection against first ever VTE event. The elevated LDL
16 cholesterol, CRP and homocysteine, as reported earlier also associate with the risk of new
17 VTE. Statins appears as a primary prevention tool in patients with a high risk of VTE, exerting
18 its best effect in male population.
19
20
21
22
23

24 **Acknowledgement**

25
26 This study was funded by University of Helsinki and The National Institute for Health and
27 Welfare, Finland (THL).
28
29

30 RL, AJ and JP have no relevant disclosures to declare. JH has had previous research
31 agreements with Janssen-Cilag, Novartis, Orion Pharma, Abbott, Novo Nordisk Farma, Pfizer,
32 Sanofi-Aventis, Astellas, and Takeda.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 Kearon C, Akl EA, Comerota AJ, *et al.* Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;**141**:e419S–94S. doi:10.1378/chest.11-2301
- 2 Squizzato A, Galli M, Romualdi E, *et al.* Statins, fibrates, and venous thromboembolism: a meta-analysis. *Eur Heart J* 2010;**31**:1248–56. doi:10.1093/eurheartj/ehp556
- 3 Glynn RJ, Danielson E, Fonseca FAH, *et al.* A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. *New England Journal of Medicine* 2009;**360**:1851–61. doi:10.1056/NEJMoa0900241
- 4 Biere-Rafi S, Hutten BA, Squizzato A, *et al.* Statin treatment and the risk of recurrent pulmonary embolism. *Eur Heart J* 2013;**34**:1800–6. doi:10.1093/eurheartj/eht046
- 5 Khemasuwan D, Divietro ML, Tangdhanakanond K, *et al.* Statins decrease the occurrence of venous thromboembolism in patients with cancer. *Am J Med* 2010;**123**:60–5. doi:10.1016/j.amjmed.2009.05.025
- 6 Akkerman JWN. From low-density lipoprotein to platelet activation. *Int J Biochem Cell Biol* 2008;**40**:2374–8. doi:10.1016/j.biocel.2008.04.002
- 7 Aromaa A, Koskinen S. Health and Functional Capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Helsinki, Finland: 2004. <http://www.terveys2000.fi/julkaisut/baseline.pdf>
- 8 Heistaro S. Methodology report : Health 2000 survey. Helsinki, Finland: : Kansanterveyslaitos 2008. <http://lib.thl.fi:2345/http://lib.thl.fi:2345/lib4/?PBFORMTYPE=01002&TITLEID=49681&SQS=1:FIN:1::6:50::HTML&PL=0>
- 9 Luotola K, Pietilä A, Zeller T, *et al.* Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. *Journal of Internal Medicine* 2011;**269**:322–32. doi:10.1111/j.1365-2796.2010.02294.x
- 10 Juonala M, Viikari JSA, Laitinen T, *et al.* Interrelations Between Brachial Endothelial Function and Carotid Intima-Media Thickness in Young Adults The Cardiovascular Risk in Young Finns Study. *Circulation* 2004;**110**:2918–23. doi:10.1161/01.CIR.0000147540.88559.00
- 11 Kauppi M, Impivaara O, Mäki J, *et al.* Vitamin D status and common risk factors for bone fragility as determinants of quantitative ultrasound variables in a nationally representative population sample. *Bone* 2009;**45**:119–24. doi:10.1016/j.bone.2009.03.659

- 1
2
3
4
5
6
7 12 WHOCC - ATC/DDD Index. http://www.whooc.no/atc_ddd_index/ (accessed 11 Sep2012).
8
9 13 Carstensen B, Plummer M, Laara E, *et al.* *Epi: A package for statistical analysis in*
10 *epidemiology*. 2008. <http://www.pubhealth.ku.dk/bxc/Epi/>
11
12 14 Cole SR, Hernan MA. Constructing Inverse Probability Weights for Marginal Structural
13 *Models*. *Am J Epidemiol* 2008;**168**:656–64. doi:10.1093/aje/kwn164
14
15 15 Danaei G, Tavakkoli M, Hernán MA. Bias in Observational Studies of Prevalent Users:
16 *Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins*. *Am J*
17 *Epidemiol* 2012;:kwr301. doi:10.1093/aje/kwr301
18
19 16 Rahimi K, Bhala N, Kamphuisen P, *et al.* Effect of Statins on Venous Thromboembolic
20 *Events: A Meta-analysis of Published and Unpublished Evidence from Randomised*
21 *Controlled Trials*. *PLoS Med* 2012;**9**:e1001310. doi:10.1371/journal.pmed.1001310
22
23 17 Ridker PM, Pradhan A, MacFadyen JG, *et al.* Cardiovascular benefits and diabetes risks of
24 *statin therapy in primary prevention: an analysis from the JUPITER trial*. *The Lancet*
25 **11**;380:565–71. doi:10.1016/S0140-6736(12)61190-8
26
27 18 Westerbacka J, Yki-Järvinen H, Turpeinen A, *et al.* Inhibition of Platelet-Collagen
28 *Interaction An In Vivo Action of Insulin Abolished by Insulin Resistance in Obesity*.
29 *Arterioscler Thromb Vasc Biol* 2002;**22**:167–72. doi:10.1161/hq0102.101546
30
31 19 Psaty BM, Siscovick DS. Minimizing Bias Due to Confounding by Indication in Comparative
32 *Effectiveness Research The Importance of Restriction*. *JAMA* 2010;**304**:897–8.
33 doi:10.1001/jama.2010.1205
34
35 20 Prandoni P, Ghirarduzzi A, Prins MH, *et al.* Venous thromboembolism and the risk of
36 *subsequent symptomatic atherosclerosis*. *Journal of Thrombosis and Haemostasis*
37 **2006**;4:1891–6. doi:10.1111/j.1538-7836.2006.02058.x
38
39 21 Prandoni P, Noventa F, Milan M. Aspirin and recurrent venous thromboembolism.
40 *Phlebology* 2013;**28 Suppl 1**:99–104. doi:10.1177/0268355512475040
41
42 22 Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of
43 *venous thrombosis: meta-analysis*. *BMJ* 2001;**323**:131. doi:10.1136/bmj.323.7305.131
44
45 23 Shufelt CL, Bairey Merz CN. Contraceptive Hormone Use and Cardiovascular Disease.
46 *Journal of the American College of Cardiology* 2009;**53**:221–31.
47 doi:10.1016/j.jacc.2008.09.042
48
49 24 Casez P, Labarère J, Sevestre M-A, *et al.* ICD-10 hospital discharge diagnosis codes were
50 *sensitive for identifying pulmonary embolism but not deep vein thrombosis*. *Journal of*
51 *Clinical Epidemiology* 2010;**63**:790–7. doi:10.1016/j.jclinepi.2009.09.002
52
53
54
55
56
57
58
59
60

Tables

Table 1 Baseline characteristics of study population

Categorical variables and usage of drugs at baseline						
Sex	male		3589			45%
	female		4336			55%
Blood glucose lowering drug	no		7637			96%
	yes		288			4%
Insulin	no		7787			98%
	yes		138			2%
Antithrombotic agent	no		7582			96%
	yes		343			4%
Antiplatelet agent	no		7764			98%
	yes		161			2%
Vitamin K antagonists	no		7732			98%
	yes		193			2%
Continuous variables at baseline LDL cholesterol (mmol/L)						
	1st Qu.	Median	Mean	3rd Qu.	SD	Missing
Age	42.0	52.0	54.7	66.0	16.1	100
Blood glucose (mmol/L)	5.0	5.3	5.6	5.7	1.3	1275
Total cholesterol (mmol/L)	5.1	5.9	5.9	6.6	1.1	1275
HDL cholesterol (mmol/L)	1.1	1.3	1.3	1.6	0.4	1275
LDL cholesterol (mmol/L)	3.1	3.8	3.8	4.5	1.2	1276
Triglycerides (mmol/L)	1.0	1.3	1.6	1.9	1.1	1275
Ratio HDL/Chol	18.0	22.0	23.0	28.0	7.4	1275
CRP (mg/L)	0.3	0.8	2.3	2.0	6.3	1694
Vitamin D3 (nmol/L)	33.0	43.0	44.9	55.0	16.9	1825
Homocysteine (µmol/L)	9.2	11.0	12.0	13.5	5.1	1825
Insulin (mU/L)	5.0	7.0	9.6	11.0	30.3	1627

Table 2. Incidence of end-point events. RR (rate ratios) with 95% confidence intervals (CI) based on univariate Poisson regression model. Laboratory measurements in tertiles "[a,b]" means that interval a-b is closed left and open right. The data on variables are collected at baseline.

Variable	P-years (1000)	Events	Incidence (1/1000)	95% CI		RR	95% CI	
Current statin usage								
no	67.78	118	1.74	1.44	2.09			
yes	11.17	18	1.61	0.95	2.55	0.93	0.56	1.52
Sex								
male	36.02	53	1.47	1.1	1.93			
female	42.93	83	1.93	1.54	2.4	1.31	0.93	1.85
Age								
(0,40]	19.92	10	0.50	0.24	0.92			
(40,50]	20.22	15	0.74	0.41	1.22	1.48	0.66	3.29
(50,60]	17.11	24	1.40	0.90	2.09	2.79	1.34	5.84
(60,70]	11.05	28	2.53	1.68	3.66	5.05	2.45	10.39
(70,Inf]	10.65	59	5.54	4.22	7.15	11.04	5.65	21.58
Insulin usage at baseline								
no	77.83	133	1.71	1.43	2.03			
yes	1.12	3	2.68	0.55	7.83	1.57	0.50	4.92
Blood glucose lowering drug								
no	76.71	124	1.62	1.34	1.93			
yes	2.24	12	5.37	2.77	9.37	3.32	1.84	6.00
Antithrombotic agent usage								
no	76.7	120	1.56	1.30	1.87			
yes	2.25	16	7.11	4.06	11.55	4.55	2.70	7.66
Antiplatelet agents usage								
no	77.87	126	1.62	1.35	1.93			
yes	1.08	10	9.27	4.44	17.05	5.73	3.01	10.91
Vitamin K antagonists usage								
no	77.7	128	1.65	1.37	1.96			
yes	1.25	8	6.42	2.77	12.66	3.90	1.91	7.97
Blood glucose (mmol/L)								
[2.4,5.1]	24.79	36	1.45	1.02	2.01			
(5.1,5.6]	23.93	31	1.30	0.88	1.84	0.89	0.55	1.44
(5.6,26.7]	18.69	48	2.57	1.89	3.40	1.77	1.15	2.72
Total cholesterol (mmol/L)								
[1.9,5.4]	23.71	36	1.52	1.06	2.10			
(5.4,6.3]	21.33	33	1.55	1.06	1.02	0.64	1.63	1.02
(6.3,11.7]	22.38	46	2.06	1.50	1.35	0.88	2.09	1.35

HDL cholesterol (mmol/L)									
[0.23,1.13]	22.39	45	2.01	1.46					
(1.13,1.45]	22.45	33	1.47	1.01	0.73	0.47	1.15	0.73	
(1.45,3.41]	22.57	37	1.64	1.15	0.82	0.53	1.26	0.82	
LDL cholesterol (mmol/L)									
[0,3.3]	22.56	34	1.51	1.04					
(3.3,4.2]	22.79	38	1.67	1.18	1.11	0.70	1.76	1.11	
(4.2,8.8]	22.06	43	1.95	1.41	1.29	0.82	2.03	1.29	
Triglycerides (mmol/L)									
[0.4,1.1]	26.16	30	1.15	0.77					
(1.1,1.7]	21.84	45	2.06	1.50	1.80	1.13	2.85	1.80	
(1.7,16.6]	19.42	40	2.06	1.47	1.80	1.12	2.88	1.80	
Ratio HDL/Chol									
[3,19]	23.92	48	2.01	1.48					
(19,25.7]	20.58	34	1.65	1.14	0.82	0.53	1.28	0.82	
(25.7,56]	22.91	33	1.44	0.99	0.72	0.46	1.12	0.72	
C-reactive protein (mg/L)									
[0,0.39]	22.26	22	0.99	0.62					
(0.39,1.41]	21.62	42	1.94	1.40	1.97	1.17	3.29	1.97	
(1.41,191]	20.53	40	1.95	1.39	1.97	1.17	3.32	1.97	
Vitamin D3 (nmol/L)									
[5,36]	20.55	35	1.70	1.19	2.37				
(36,50]	21.42	31	1.45	0.98	2.06	0.85	0.52	1.38	
(50,134]	21.15	37	1.75	1.23	2.41	1.03	0.65	1.63	
Homocysteine (µmol/L)									
[3.7,9.7]	22.15	18	0.81	0.48	1.29				
(9.7,12.5]	21.82	32	1.47	1.00	2.07	1.80	1.01	3.22	
(12.5,111]	19.16	53	2.77	2.07	3.62	3.40	1.99	5.81	
Insulin (mU/L)									
[1,5]	22.72	26	1.14	0.75	1.68				
(5,9]	22.67	45	1.99	1.45	2.66	1.73	1.07	2.81	
(9,2200]	19.64	33	1.68	1.16	2.36	1.47	0.88	2.00	

Table 3. Rate ratios (RR) with 95% confidence intervals (CI) of three Poisson regression models. Model I included only statin, age and sex as covariates. Models II and III included also Blood glucose lowering drug, Insulin usage, Vitamin K antagonists usage, and Antiplatelet agents usage as covariates. Inverse Probability Weights (IPW) Model III is based on stabilized weights for statin usage. In IPW model age and sex were in numerator, and age, sex, baseline oral antidiabetics, baseline insulin, and baseline anticoagulant usage were in denominator.

		Model I			Model II			Model III		
		RR (95% CI)			RR (95% CI)			RR, IPW (95% CI)		
Statin	no	(reference)			(reference)			(reference)		
	current	0.64	0.38	1.05	0.60	0.36	1.00	0.58	0.35	0.96
Age	under 40	(reference)			(reference)			(reference)		
	(40,50]	1.52	0.68	3.38	1.51	0.68	3.37	1.53	0.68	3.43
	(50,60]	2.99	1.42	6.26	2.91	1.39	6.10	3.20	1.53	6.70
	(60,70]	5.66	2.73	11.75	5.31	2.55	11.05	5.36	2.55	11.24
	(70,Inf]	11.68	5.94	22.95	9.92	4.99	19.74	9.93	4.95	19.92
Sex	male	(reference)			(reference)			(reference)		
	female	1.02	0.72	1.45	1.02	0.72	1.46	0.99	0.70	1.41
Blood glucose lowering drug	no	(reference)			(reference)			(reference)		
	yes				1.89	0.98	3.63	1.63	0.86	3.11
Insulin usage	no	(reference)			(reference)			(reference)		
	yes				0.72	0.21	2.45	0.72	0.25	2.13
Vitamin K antagonists	no	(reference)			(reference)			(reference)		
	yes				1.46	0.69	3.07	1.38	0.68	2.80
Antiplatelet agents	no	(reference)			(reference)			(reference)		
	yes				2.33	1.20	4.53	2.60	1.42	4.76

Table 4. Statin usage and sex, interaction model. Model included age, Blood glucose lowering drug, Insulin usage, Vitamin K antagonists usage, and Antiplatelet agents usage as covariates.

	P-years	Events	Incidence (95% CI)			RR (95% CI)		
no statin/male	30.57	50	1.64	1.21	2.16	(reference)		
statin/male	5.45	3	0.55	0.11	1.61	0.20	0.06	0.65
no statin/female	37.21	68	1.83	1.42	2.32	0.87	0.60	1.27
statin/female	5.72	15	2.62	1.47	4.33	0.75	0.41	1.38

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract Statin use associates with a reduced incidence of venous thromboembolism – A population-based cohort study (b) Provide in the abstract an informative and balanced summary of what was done and what was found Done
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Done
Objectives	3	State specific objectives, including any prespecified hypotheses Done
Methods		
Study design	4	Present key elements of study design early in the paper Done
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Done
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Done (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Done
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Done
Bias	9	Describe any efforts to address potential sources of bias Done
Study size	10	Explain how the study size was arrived at Done
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Done
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding Done (b) Describe any methods used to examine subgroups and interactions Done (c) Explain how missing data were addressed Done (d) If applicable, explain how loss to follow-up was addressed Done (e) Describe any sensitivity analyses Done

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Done
		(b) Give reasons for non-participation at each stage Done
		(c) Consider use of a flow diagram Not included, presented in previous papers
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Done
		(b) Indicate number of participants with missing data for each variable of interest Done
		(c) Summarise follow-up time (eg, average and total amount) Done
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Done, 95% Ci given, interaction test with p-value and X2 test.
		(b) Report category boundaries when continuous variables were categorized Done
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not done because of brevity. Easy to do if needed with data in tables.
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Done
Discussion		
Key results	18	Summarise key results with reference to study objectives Done
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Done
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Done
Generalisability	21	Discuss the generalisability (external validity) of the study results Done. This is population based study.
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Details give, not extra funding.

*Give information separately for exposed and unexposed groups.

1 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and
2 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely
3 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at
4 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is
5 available at <http://www.strobe-statement.org>.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only